Courtney D. DiNardo, M.D., MSCE

Peer-Reviewed Articles

1. Mill, CP, Fiskus, WC, DiNardo, C, Reville, PK, Davis, JA, Birdwell, C, Das, K, Hou, H, Takahashi, K, Flores, L, Ruan, X, Su, X, Loghavi, S, Khoury, J, Bhalla, K. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood cancer journal 14(1), 2024. PMID: 38316746.
2. Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, Tomalin LE, Cruz-Rodriguez N, Wang T, Olszewska M, Olivier E, Jaud M, Nadorp B, Kroger B, Hu F, Silverman L, Chung SS, Wagenblast E, Chaligne R, Eisfeld AK, Demircioglu D, Landau DA, Lito P, Papaemmanuil E, DiNardo CD, Hasson D, Konopleva M, Papapetrou EP. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature None(None):None, 2024. PMID: 39478230.
3. Gener-Ricos, G, Bataller, A, Rodriguez-Sevilla, JJ, Chien, KS, Quesada, AE, Almanza-Huante, E, Hammond, DE, Sasaki, K, DiNardo, C, Kadia, TM, Daver, N, Borthakur, G, Issa, GC, Short, NJ, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. PMID: 38896064.
4. Senapati, J, Kantarjian, HM, Bazinet, A, Reville, PK, Short, NJ, Daver, N, Borthakur, G, Bataller, A, Jabbour, EJ, DiNardo, C, Haddad, FG, Sasaki, K, Popat, UR, Oran, B, Alousi, AM, Loghavi, S, Shpall, E, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. PMID: 38809547.
5. DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, Verma A, Konopleva M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer 5(10):1515-1533, 2024. PMID: 39300320.
6. Loghavi S, Wei Q, Ravandi F, Quesada AE, Routbort MJ, Hu S, Toruner GA, Wang SA, Wang W, Miranda RN, Li S, Xu J, DiNardo CD, Daver N, Kadia TM, Issa GC, Kantarjian HM, Medeiros LJ, Tang G. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol 99(10):1959-1968, 2024. PMID: 39016111.
7. Gutierrez-Rodrigues F, Groarke EM, Thongon N, Rodriguez-Sevilla JJ, Bazzo Catto LF, Niewisch MR, Shalhoub RN, McReynolds LJ, Cle DV, Patel BA, Ma X, Hironaka D, Donaires FS, Spitofsky NR, Santana BA, Lai TP, Alemu L, Kajigaya S, Darden I, Zhou W, Browne PV, Paul S, Lack J, Young DJ, DiNardo CD, Aviv A, Ma F, Michels de Oliveira M, Azambuja AP, Dunbar CE, Olszewska M, Olivier E, Papapetrou EP, Giri N, Alter BP, Bonfim CMS, Wu CO, Garcia-Manero G, Savage SA, Young NS, Colla S, Calado RT. Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescuing and cancer mutations. Blood None(None):None, 2024. PMID: 39316766.
8. Bouligny IM, DiNardo CD. Oral decitabine-cedazuridine in acute myeloid leukaemia. Br J Haematol None(None):None, 2024. PMID: 39313925.
9. Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma 65(9):1344-1349, 2024. PMID: 38696743.
10. DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, de Botton S, Stein A, Foran JM, Arellano ML, Sallman DA, Hossain M, Marchione DM, Bai X, Patel PA, Kapsalis SM, Garcia-Manero G, Fathi AT. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Adv 8(15):4209-4220, 2024. PMID: 38640348.
11. Dohner H, DiNardo CD, Wei AH, Lowenberg B, Appelbaum F, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood None(None):None, 2024. PMID: 39133932.
12. Issa GC, Stein EM, DiNardo CDD. How I Treat: Differentiation Therapy in Acute Myeloid Leukemia. Blood None(None):None, 2024. PMID: 38976876.
13. Bundrant, BE, Gerstein, YS, Arun, BK, DiNardo, C. Hematologic malignancies in Li–Fraumeni syndrome. American Journal of Medical Genetics, Part A 194(7), 2024. PMID: 38410872.
14. DiNardo, C, Olin, R, Wang, ES, Skikne, B, Rosenthal, J, Kumar, P, Sumi, H, Hizukuri, Y, Hong, Y, Patel, P, Seki, T, Duan, T, Lesegretain, A, Andreeff, M. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer medicine 13(14), 2024. PMID: 39030997.
15. Bataller, A, Gener-Ricos, G, Almanza-Huante, E, Chien, KS, Urrutia, S, Bazinet, A, Rodriguez-Sevilla, JJ, Hammond, DE, Sasaki, K, Takahashi, K, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Kadia, TM, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Advances 8(11):2695-2706, 2024. PMID: 38513082.
16. Dinh, A, Savoy, JM, Kontoyiannis, DP, Takahashi, K, Issa, GC, Kantarjian, HM, DiNardo, C, Rausch, CR. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 130(11):1964-1971, 2024. PMID: 38340331.
17. Sasaki, K, Ravandi-Kashani, F, Kadia, TM, DiNardo, C, Yilmaz, M, Short, NJ, Jabbour, EJ, Patel, KP, Loghavi, S, Pierce, S, Borthakur, G, Kantarjian, HM. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(6):375-381, 2024. PMID: 38431521.
18. Jen, WY, Sasaki, K, Loghavi, S, Wang, S, Qiao, W, Borthakur, G, Ravandi-Kashani, F, Kadia, TM, Issa, GC, Short, NJ, Yilmaz, M, Daver, N, DiNardo, C. Characteristics and outcomes of acute myeloid leukemia patients with baseline CD7 expression. British Journal of Haematology 204(6):2259-2263, 2024. PMID: 38603594.
19. Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. PMID: 38804782.
20. Montesinos, P, Fathi, AT, De Botton, S, Stein, EM, Zeidan, AM, Zhu, Y, Prebet, T, Vigil, CE, Bluemmert, I, Yu, X, DiNardo, C. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib. Blood Advances 8(10):2509-2519, 2024. PMID: 38507688.
21. Fiskus, WC, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Mill, CP, Birdwell, C, Das, K, Davis, JA, Hou, H, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Reville, PK, Wang, J, Loghavi, S, Sen, R, Ruan, X, Su, X, Flores, L, DiNardo, C, Bhalla, K. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood 143(20):2059-2072, 2024. PMID: 38437498.
22. Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica None(None):None, 2024. PMID: 38695144.
23. Risueno, A, See, WL, Bluemmert, I, De Botton, S, DiNardo, C, Fathi, AT, Schuh, A, Montesinos, P, Vyas, P, Prebet, T, Gandhi, AK, Hasan, M. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Leukemia Research 140, 2024. PMID: 38564986.
24. Pasvolsky, O, Saliba, RM, Popat, UR, Alousi, AM, Mehta, RS, Yeh, JC, Al-Atrash, G, Adeel, M, Ramdial, JL, Marin, D, Rondon, G, Kebriaei, P, Champlin, RE, Daver, N, DiNardo, C, Short, NJ, Shpall, E, Oran, B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 24(5):e196-e204, 2024. PMID: 38403505.
25. Short, NJ, Daver, N, DiNardo, C, Kadia, TM, Nasr, L, Macaron, W, Yilmaz, M, Borthakur, G, Montalban Bravo, G, Garcia-Manero, G, Issa, GC, Chien, KS, Jabbour, EJ, Nasnas, C, Huang, X, Qiao, W, Matthews, JA, Stojanik, CJ, Patel, KP, Abramova, R, Thankachan, J, Konopleva, M, Kantarjian, HM, Ravandi-Kashani, F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML. Journal of Clinical Oncology 42(13):1499-1508, 2024. PMID: 38277619.
26. Pratz, K, Jonas, BA, Pullarkat, V, Thirman, MJ, Garcia, JS, Döhner, H, Recher, C, Fiedler, W, Yamamoto, K, Wang, J, Sung, SY, Wolach, O, Yeh, S, Leber, B, Esteve, J, Mayer, J, Porkka, K, Illés, Á, Lemoli, RM, Turgut, M, Ku, GH, Miller, CL, Zhou, Y, Zhang, M, Chyla, B, Potluri, J, DiNardo, C. Long-term follow-up of VIALE-A. American journal of hematology 99(4):615-624, 2024. PMID: 38343151.
27. Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. The Lancet Haematology 11(4):e276-e286, 2024. PMID: 38452788.
28. Bazinet, A, Desikan, SP, Li, Z, Rodriguez-Sevilla, JJ, Venugopal, S, Urrutia, S, Montalban Bravo, G, Sasaki, K, Chien, KS, Hammond, DE, Kanagal Shamanna, R, Ganan Gomez, I, Kadia, TM, Borthakur, G, DiNardo, C, Daver, N, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clinical Cancer Research 30(7):1319-1326, 2024. PMID: 38300723.
29. Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. The Lancet Haematology 11(4):e287-e298, 2024. PMID: 38548404.
30. Chien, KS, Ong, F, Kim, K, Li, Z, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Montalban Bravo, G, Hammond, DE, Sasaki, K, Pierce, SA, Kantarjian, HM, Garcia-Manero, G. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer medicine 13(5), 2024. PMID: 38497538.
31. Birdwell, C, Fiskus, WC, Kadia, TM, Mill, CP, Sasaki, K, Daver, N, DiNardo, C, Pemmaraju, N, Borthakur, G, Davis, JA, Das, K, Sharma, S, Horrigan, SK, Ruan, X, Su, X, Khoury, J, Kantarjian, HM, Bhalla, K. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 38(3):545-556, 2024. PMID: 38086946.
32. Bataller, A, Bazinet, A, DiNardo, C, Maiti, A, Borthakur, G, Daver, N, Short, NJ, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Takahashi, K, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Advances 8(4):927-935, 2024. PMID: 38113472.
33. Jabbour, EJ, Haddad, FG, Short, NJ, Senapati, J, Jain, N, Sasaki, K, Jorgensen, JL, Wang, SA, Alvarado, Y, Wang, X, DiNardo, C, Masarova, L, Kadia, TM, Garris, R, Ravandi-Kashani, F, Kantarjian, HM. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417-421, 2024. PMID: 37879077.
34. Jen, WY, Sasaki, K, Rausch, CR, DiNardo, C, Kadia, TM, Yilmaz, M, Borthakur, G, Alvarado, Y, McCue, D, McCue, D, Kantarjian, HM, Ravandi-Kashani, F. Acute kidney injury in acute promyelocytic leukemia. Leukemia and Lymphoma 65(3):378-382, 2024. PMID: 38054837.
35. Senapati, J, Muftuoglu, M, Ishizawa, J, Abbas, HA, Loghavi, S, Borthakur, G, Yilmaz, M, Issa, GC, Dara, S, Basyal, M, Li, L, Naqvi, K, Pourebrahim, R, Jabbour, EJ, Kornblau, SM, Short, NJ, Pemmaraju, N, Garcia-Manero, G, Ravandi-Kashani, F, Khoury, J, Daver, N, Kantarjian, HM, Andreeff, M, DiNardo, C. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia. Blood cancer journal 13(1), 2023. PMID: 37386016.
36. Short, NJ, Muftuoglu, M, Ong, F, Nasr, L, Macaron, W, Montalban Bravo, G, Alvarado, Y, Basyal, M, Daver, N, DiNardo, C, Borthakur, G, Jain, N, Ohanian, M, Jabbour, EJ, Issa, GC, Qiao, W, Huang, X, Kanagal Shamanna, R, Patel, KP, Bose, P, Ravandi-Kashani, F, Delumpa, R, Abramova, R, Garcia-Manero, G, Andreeff, M, Cortes, JE, Kantarjian, HM. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of Hematology and Oncology 16(1), 2023. PMID: 37422688.
37. Sasaki, K, Ravandi-Kashani, F, DiNardo, C, Welch, MA, Kadia, TM, Kantarjian, HM. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 23(12):905-910, 2023. PMID: 37730483.
38. Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce SA, Chien KS, Sasaki K, Kadia TM, Hammond D, Borthakur G, Patel KP, Ravandi F, Kantarjian HM, Garcia-Manero G, CD D. Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
39. Bataller, A, Loghavi, S, Gerstein, YS, Bazinet, A, Sasaki, K, Chien, KS, Hammond, DE, Montalban Bravo, G, Borthakur, G, Short, NJ, Issa, GC, Kadia, TM, Daver, N, Tang, G, Quesada, AE, Patel, KP, Ravandi, F, Fiskus, WC, Mill, CP, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Oran, B, DiNardo, C. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American journal of hematology 98(11):1780-1790, 2023. PMID: 37665752.
40. Sasaki, K, Morita, K, Kantarjian, HM, Garcia-Manero, G, Jabbour, EJ, Ravandi, F, Konopleva, M, Borthakur, G, Wierda, WG, Daver, N, Takahashi, K, DiNardo, C, Montalban Bravo, G, Issa, GC, Pierce, S, Soltysiak, KA, Tingen, MS, Cortes, JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades. Clinical Lymphoma, Myeloma and Leukemia 23(11):e369-e378, 2023. PMID: 37690903.
41. Montalban Bravo, G, Kanagal Shamanna, R, Li, Z, Hammond, DE, Chien, KS, Rodriguez-Sevilla, JJ, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology 203(4):581-592, 2023. PMID: 37608562.
42. Kadia, TM, Ravandi-Kashani, F, Molica, M, Bataller, A, Borthakur, G, Daver, N, Jabbour, EJ, DiNardo, C, Pemmaraju, N, Jain, N, Ferrajoli, A, Ylimaz, M, Bose, P, Tidwell, R, Marx, KR, Rausch, CR, Kanagal Shamanna, R, Wang, S, Islam, R, Champlin, RE, Shpall, E, Konopleva, M, Garcia-Manero, G, Kantarjian, HM. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. American journal of hematology 98(11):1711-1720, 2023. PMID: 37635400.
43. Senapati, J, Fiskus, WC, Daver, N, Wilson, NR, Ravandi-Kashani, F, Garcia-Manero, G, Kadia, TM, DiNardo, C, Jabbour, EJ, Burger, JA, Short, NJ, Alvarado, Y, Jain, N, Masarova, L, Issa, GC, Qiao, W, Khoury, J, Pierce, SR, Miller, D, Sasaki, K, Konopleva, M, Bhalla, K, Borthakur, G, Pemmaraju, N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clinical Cancer Research 29(21):4352-4360, 2023. PMID: 37585491.
44. Homan, CC, Drazer, MW, Yu, K, Lawrence, DM, Feng, J, Arriola-Martinez, L, Pozsgai, M, McNeely, K, Ha, T, Venugopal, P, Arts, P, King-Smith, SL, Cheah, J, Armstrong, M, Wang, PP, Bödör, C, Cantor, A, Cazzola, M, Degelman, E, DiNardo, C, Duployez, N, Favier, R, Fröhling, S, Rio-Machin, A, Klco, JM, Krämer, A, Kurokawa, M, Lee, J, Malcovati, L, Morgan, NV, Natsoulis, G, Owen, C, Patel, KP, Preudhomme, C, Raslova, H, Rienhoff, HY, Ripperger, T, Schulte, R, Tawana, K, Velloso, EP, Yan, B, Kim, E, Sood, R, Hsu, AP, Holland, SM, Phillips, K, Poplawski, NK, Babic, M, Wei, A, Forsyth, C. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Advances 7(20):6092-6107, 2023. PMID: 37406166.
45. Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica 108(9):2331-2342, 2023. e-Pub 2023. PMID: 36951163.
46. Bazinet, A, Kantarjian, HM, Arani, N, Popat, U, Bataller, A, Sasaki, K, DiNardo, C, Daver, N, Yilmaz, M, Abbas, HA, Short, NJ, Issa, GC, Jabbour, EJ, Pierce, S, Chen, J, Garcia, R, Konopleva, M, Garcia-Manero, G, Alousi, A, Shpall, EJ, Champlin, RE, Borthakur, G, Ravandi-Kashani, F, Kadia, TM. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. American journal of hematology 98(9):1383-1393, 2023. PMID: 37334870.
47. Jelloul FZ, Routbort MJ, CD D, Bueso-Ramos CE, Kanagal-Shamanna R, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, You MJ, Patel KP, Medeiros LJ, Quesada AE. DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol 98(8):E193-E196, 2023. e-Pub 2023. PMID: 37154083.
48. Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, Daver NG, Alvarado Y, Haddad FG, Pierce SR, Nogueras Gonzalez GM, Maiti A, Sasaki K, Yilmaz M, Thompson PA, Wierda WG, Garcia-Manero G, Andreeff M, Jabbour EJ, Konopleva MY, Huang X, Kantarjian HM, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
49. Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res 11(7):1011-1028, 2023. e-Pub 2023. PMID: 37163233.
50. Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 4(4):276-293, 2023. e-Pub 2023. PMID: 37102976.
51. Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, CD D, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic Stem Cell Transplantation. Blood Adv 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
52. Urrutia, S, Li, Z, Almanza, E, Bataller, A, Kanagal Shamanna, R, Senapati, J, Sasaki, K, Chien, KS, Montalban Bravo, G, DiNardo, C, Borthakur, G, Bueso-Ramos, CE, Pierce, S, Kantarjian, HM, Garcia-Manero, G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37(6):1397-1400, 2023. PMID: 37185307.
53. Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. e-Pub 2023. PMID: 36892949.
54. CD D, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2022. PMID: 35973199.
55. Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer 129(12):1866-1872, 2023. e-Pub 2023. PMID: 36882573.
56. Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia 37(6):1336-1348, 2023. e-Pub 2023. PMID: 36977823.
57. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
58. Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res:OF1-OF18. e-Pub 2023. PMID: 37285177.
59. Jabbour E, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, CD D, Patel K, Kanagal-Shamanna R, Champlin R, Khouri I, Dellasala S, Pierce SA, Kantarjian H. The Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line BCR::ABL1 Tyrosine Kinase Inhibitors. Am J Hematol 98(4):658-665, 2023. e-Pub 2023. PMID: 36683287.
60. Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. e-Pub 2023. PMID: 36715486.
61. Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J 13(1):53, 2023. e-Pub 2023. PMID: 37055414.
62. Issa GC, Bidikian A, Venugopal S, Konopleva MY, CD D, Kadia TM, Borthakur G, Jabbour EJ, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce SR, Takahashi K, Tang G, Loghavi S, Patel KP, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver NG. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2022. PMID: 36322818.
63. Abbas HA, Sun H, Pierce SR, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour EJ, Konopleva MY, Short NJ, CD D, Daver NG, Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv 7(5):828-831, 2023. e-Pub 2022. PMID: 35405739.
64. CD D, Hochhaus A, Frattini MG, Yee K, Zander T, Krämer A, Chen X, Ji Y, Parikh NS, Choi J, Wei AH. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. J Cancer Res Clin Oncol 149(3):1145-1158, 2023. e-Pub 2022. PMID: 35353219.
65. Tomaszowski KH, Roy S, Guerrero C, Shukla P, Keshvani C, Chen Y, Ott M, Wu X, Zhang J, DiNardo CD, Schindler D, Schlacher K. Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress. Nat Commun 14(1):1333, 2023. e-Pub 2023. PMID: 36906610.
66. Trabal A, Gibson A, He J, McCall D, Roth M, Nuñez C, Garcia M, Buzbee M, Toepfer L, Bidikian A, Daver N, Kadia T, Short NJ, Issa GC, Ravandi F, DiNardo CD, Montalban Bravo G, Garces S, Marcogliese A, Paek H, Dreyer Z, Brackett J, Redell M, Yi J, Garcia-Manero G, Konopleva M, Stevens A, Cuglievan B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers (Basel) 15(7), 2023. e-Pub 2023. PMID: 37046645.
67. Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, CD D, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
68. Yennurajalingam S, Konopleva M, Carmack CL, CD D, Gaffney M, Michener HK, Lu Z, Stanton P, Ning J, Qiao W, Bruera E. Treatment of Cancer-related-Fatigue in Acute Hematological Malignancies: Results of a Feasibility Study of using Cognitive Behavioral Therapy. J Pain Symptom Manage 65(3):e189-e197, 2023. e-Pub 2022. PMID: 36384181.
69. Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, CD D, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2022. PMID: 36458426.
70. Zeng Z, Maiti A, Herbrich S, Cai T, Cavazos A, Manzella T, Ma H, Hayes K, Matthews J, CD D, Daver NG, Konopleva MY. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. Cancer 129(4):531-540, 2023. e-Pub 2022. PMID: 36477735.
71. Figueroa M, Ma H, Alfayez M, Morales-Mantilla DE, Wang F, Lu Y, Estecio M, King KY, Kleinerman ES, Moghaddam SJ, Daver NG, Andreeff M, Konopleva MY, CD D, Chandra J. Cigarette smoke exposure accelerates AML progression in FLT3-ITD models. Blood Adv 7(21):6624-6629, 2023. e-Pub 2023. PMID: 37486624.
72. Aminu, M, Daver, N, Godoy, M, Shroff, G, Wu, CC, Torre-Sada, LF, Goizueta, AA, Shannon, VR, Faiz, S, Altan, M, Garcia-Manero, G, Kantarjian, HM, Ravandi-Kashani, F, Kadia, TM, Konopleva, M, DiNardo, C, Pierce, S, Naing, A, Kim, ST, Kontoyiannis, DP, Khawaja, F, Chung, C, Wu, J, Sheshadri, A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia. Frontiers in immunology 14, 2023. PMID: 37841255.
73. Morse JW, Rios M, Ye J, Rios A, Zhang CC, Daver NG, CD D, Zhang N, An Z. Antibody Therapies for the Treatment of Acute Myeloid Leukemia: Exploring Current and Emerging Therapeutic Targets. Expert Opin Investig Drugs 32(2):107-125, 2023. e-Pub 2023. PMID: 36762937.
74. Johnson AQ, Bannon SA, Farach LS, Hyde SM, Hashmi SS, Wagner C, CD D. Assessing patient attitudes toward genetic testing for hereditary hematologic malignancy. Eur J Haematol 110(1):109-116, 2023. e-Pub 2022. PMID: 36209474.
75. de Botton S, Montesinos P, Schuh AC, Papayannidis C, Vyas P, Wei AH, Ommen H, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol F, Chromik J, Byrne J, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin V, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martin-Regueira P, CD D. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood 141(2):156-167, 2023. PMID: 35714312.
76. Gener-Ricos G, Gerstein YS, Hammond D, DiNardo CD. Germline Predisposition to Myelodysplastic Syndromes. Cancer J 29(3):143-151, 2023. PMID: 37195770.
77. Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, CD D. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine. Clin Cancer Res 28(24):5272-5279, 2022. e-Pub 2022. PMID: 36007102.
78. Rivera, D, Kim, K, Kanagal Shamanna, R, Borthakur, G, Montalban Bravo, G, Daver, N, DiNardo, C, Short, NJ, Yilmaz, M, Pemmaraju, N, Takahashi, K, Jabbour, EJ, Pierce, S, Konopleva, M, Bhalla, K, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. American journal of hematology 97(12):1599-1606, 2022. PMID: 36117258.
79. Short, NJ, Venugopal, S, Qiao, W, Kadia, TM, Ravandi-Kashani, F, Macaron, W, DiNardo, C, Daver, N, Konopleva, M, Borthakur, G, Shpall, E, Popat, UR, Champlin, RE, Mehta, RS, Al-Atrash, G, Oran, B, Jabbour, EJ, Garcia-Manero, G, Issa, GC, Montalban Bravo, G, Yilmaz, M, Maiti, A, Kantarjian, HM. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Journal of Hematology and Oncology 15(1), 2022. PMID: 35093134.
80. Zhang, Q, Riley-Gillis, B, Han, L, Jia, Y, Lodi, A, Zhang, H, Ganesan, S, Pan, R, Konoplev, SN, Sweeney, SR, Ryan, J, Jitkova, Y, Dunner, K, Grosskurth, SE, Vijay, P, Ghosh, S, Lu, C, Ma, W, Kurtz, S, Ruvolo, VR, Ma, H, Weng, C, Ramage, CL, Baran, N, Shi, C, Cai, T, Davis, RE, Battula, VL, Mi, YC, Wang, J, DiNardo, C, Andreeff, M, Tyner, JW, Schimmer, AD, Letai, AG, Padua, RA, Bueso-Ramos, CE, Tiziani, S, Leverson, JD, Popovic, R, Konopleva, M. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduction and Targeted Therapy 7(1), 2022. PMID: 35185150.
81. Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Jiang Q, Sun Y, Chyla B, Mendes W, DiNardo CD. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood 140(25):2754-2756, 2022. PMID: 36112968.
82. Venugopal S, CD D, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
83. Borthakur, G, Ravandi-Kashani, F, Patel, KP, Wang, X, Kadia, TM, DiNardo, C, Garcia-Manero, G, Pemmaraju, N, Jabbour, EJ, Takahashi, K, Ohanian, M, Daver, N, Alvarado, Y, Brandt, M, Pierce, S, Kantarjian, HM. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia. American journal of hematology 97(11):1427-1434, 2022. PMID: 36053747.
84. Jonas, BA, DiNardo, C, Fracchiolla, N, Pristupa, A, Ishizawa, KI, Jin, J, Konopleva, M, Ofran, Y, Montesinos, P, Kovacsovics, T, Jang, JH, Kantarjian, HM, Duan, Y, Potluri, J, Werner, M, Pratz, K. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. American journal of hematology 97(11):E422-E425, 2022. PMID: 36053878.
85. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, CD D, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):3848-3857, 2022. e-Pub 2022. PMID: 35704787.
86. Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, CD D, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia 36(11):2729-2733, 2022. e-Pub 2022. PMID: 36151141.
87. Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, Stevens D, Kantarjian H, Traina F, Venditti A, Mayer J, Montez M, Jin H, Duan Y, Brackman D, Zha J, Potluri J, Werner M, Jonas BA. Postremission cytopenia management in patients with AML treated with venetoclax and azacitidine in VIALE-A. Am J Hematol 97(11):E416-E419, 2022. e-Pub 2022. PMID: 36054316.
88. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, CD D. Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
89. Duncavage EJ, Bagg A, Hasserjian RP, CD D, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji R, Lee-Cheun Loh M, Loghavi S, Mullighan CG, Ogawa S, Orazi A, Papaemmanuil E, Reiter A, Ross DM, Savona M, Shimamura A, Skoda RC, Solé F, Stone RM, Tefferi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood 140(21):2228-2247, 2022. PMID: 36130297.
90. Bidikian, A, Kantarjian, HM, Dabaja, BS, Ravandi-Kashani, F, Jabbour, EJ, DiNardo, C, Borthakur, G, Daver, N, Garcia-Manero, G, Kadia, TM, Sasaki, K, Issa, GC. AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. Clinical Lymphoma, Myeloma and Leukemia 22:S233-S234, 2022. PMID: 36163805.
91. Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, G, Garcia, JS, Bose, P, Jabbour, EJ, Ravandi-Kashani, F, Daver, N, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, DiNardo, C. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S240-S241, 2022. PMID: 36163821.
92. Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. PMID: 36163813.
93. Ong, F, Kim, K, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Kadia, TM, Jabbour, EJ, Short, NJ, Hammond, DE, Pemmaraju, N, Pierce, S, Montalban Bravo, G, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH). Clinical Lymphoma, Myeloma and Leukemia 22:S319, 2022. PMID: 36163972.
94. Abuasab, T, Mohamed, SF, Biostatistics, HH, Biostatistics, XW, Sasaki, K, Yilmaz, M, Kadia, TM, DiNardo, C, Daver, N, Pemmaraju, N, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, Takahashi, K. AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD). Clinical Lymphoma, Myeloma and Leukemia 22:S243, 2022. PMID: 36163827.
95. DiNardo, C, Pratz, K, Panayiotidis, P, Wei, X, Vorobyev, V, Illés, Á, Kim, I, Ivanov, V, Ku, GH, Miller, CL, Zhang, M, Tatsch, F, Potluri, J, Schmidt, X, Recher, C. AML-119 The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use (G-CSFu) in the Phase 3 Studies of Venetoclax (Ven) Combination Treatments in Patients (Pts) With Newly Diagnosed Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia 22:S214, 2022. PMID: 36163767.
96. Ong, F, Kadia, TM, Short, NJ, Yilmaz, M, Alvarado, Y, Sasaki, K, Pierce, S, Garcia-Manero, G, DiNardo, C, Borthakur, G, Konopleva, M, Daver, N, Kantarjian, HM, Ravandi-Kashani, F. AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). Clinical Lymphoma, Myeloma and Leukemia 22:S258, 2022. PMID: 36163855.
97. Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. PMID: 36163817.
98. DiNardo, C, De Botton, S, Risueno, A, Schuh, A, Löwenberg, B, Kim, HJ, Vyas, P, Wei, A, Stein, EM, Döhner, H, Fathi, AT, Martin-Regueira, P, Taningco, L, Bluemmert, I, Yu, X, See, WL, Hasan, M. AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial. Clinical Lymphoma, Myeloma and Leukemia 22:S249-S250, 2022. PMID: 36163838.
99. Abuasab, T, Senapati, J, Kadia, TM, Ravandi-Kashani, F, DiNardo, C, Pemmaraju, N, Ohanion, M, Alvarado, Y, Kantarjian, HM, Borthakur, G. AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)– Based Regimen. Clinical Lymphoma, Myeloma and Leukemia 22:S235-S236, 2022. PMID: 36163808.
100. Venugopal S, Borthakur G, Daver N, CD D, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv 6(19):5546-5549, 2022. PMID: 35201293.
101. Rausch CR, DiPippo AJ, Jiang Y, CD D, Kadia T, Maiti A, Montalban-Bravo G, Ravandi F, Kontoyiannis DP. Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. Clin Infect Dis 75(9):1503-1510, 2022. e-Pub 2022. PMID: 35325094.
102. Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, Nguyen AT, Miller PG, McConkey ME, Quevedo Barrios VA, Furudate K, Zhang L, Kanagal-Shamanna R, Zhang J, Little L, Gumbs C, Daver N, CD D, Kadia T, Ravandi F, Kantarjian H, Garcia-Manero G, Futreal PA, Ebert BL, Takahashi K. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood 140(16):1753-1763, 2022. e-Pub 2022. PMID: 35512188.
103. Döhner, H, Wei, A, Appelbaum, F, Craddock, C, DiNardo, C, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, GJ, Röllig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, J, Wierzbowska, A, Löwenberg, B. Diagnosis and management of AML in adults. Blood 140(12):1345-1377, 2022. PMID: 35797463.
104. Arber, DA, Orazi, A, Hasserjian, RP, Borowitz, MJ, Calvo, KR, Kvasnicka, HM, Wang, S, Bagg, A, Barbui, T, Branford, S, Bueso-Ramos, CE, Cortes, JE, Dal Cin, P, DiNardo, C, Dombret, H, Duncavage, E, Ebert, BL, Estey, E, Facchetti, F, Foucar, K, Gangat, N, Gianelli, U, Godley, LA, Gökbuget, N, Gotlib, J, Hellström-Lindberg, E, Hobbs, GS, Hoffman, R, Jabbour, EJ, Kiladjian, JJ, Larson, RA, Le Beau, MM, Loh, M, Löwenberg, B, Macintyre, E, Malcovati, L, Mullighan, CG, Niemeyer, CM, Odenike, O, Ogawa, S, Orfao, A, Papaemmanuil, E, Passamonti, F, Porkka, K, Pui, CH, Radich, JP, Reiter, A, Rozman, M, Rudelius, M, Savona, MR, Schiffer, CA, Schmitt-Gräff, A, Shimamura, A, Sierra, J, Stock, W, Stone, RM, Tallman, MS, Thiele, J, Tien, HF, Tzankov, A, Vannucchi, AM, Vyas, P, Wei, A, Weinberg, OK, Wierzbowska, A, Cazzola, M, Döhner, H, Tefferi, A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. Blood 140(11):1200-1228, 2022. PMID: 35767897.
105. Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, CD D, Kadia TM, Ravandi F, Sasaki K, Begna KH. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol 97(9):1127-1134, 2022. e-Pub 2022. PMID: 35702875.
106. Jonas BA, Wei AH, Recher C, CD D, Jang JH, Pratz K, Panayiotidis P, Montesinos P, Yeh SP, Ivanov V, Fiedler W, Yamauchi T, Duan Y, Mendes W, Potluri J, Tews B, Ofran Y. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):E299-E303, 2022. e-Pub 2022. PMID: 35567776.
107. Wang X, Tang G, Hu Z, Fang H, Wang W, Tang Z, Toruner GA, Zhou T, CD D, Garcia-Manero G, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Hu S. Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival. Br J Haematol 198(3):604-608, 2022. e-Pub 2022. PMID: 35645146.
108. CD D, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
109. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, CD D, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer 128(14):2736-2745, 2022. e-Pub 2022. PMID: 35452134.
110. Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, Pollyea DA, CD D, Wei AH. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv 6(13):3879-3883, 2022. e-Pub 2022. PMID: 35511730.
111. Sasaki, K, Ravandi-Kashani, F, Kadia, TM, DiNardo, C, Borthakur, G, Short, NJ, Jain, N, Daver, N, Jabbour, EJ, Garcia-Manero, G, Khoury, J, Konoplev, SN, Loghavi, S, Patel, KP, Montalban Bravo, G, Masarova, L, Konopleva, M, Kantarjian, HM. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American journal of hematology 97(7):865-876, 2022. PMID: 35384048.
112. Haddad, FG, Sasaki, K, Issa, GC, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM, Cortes, JE, Konopleva, M, Pemmaraju, N, Alvarado, Y, Yilmaz, M, Borthakur, G, DiNardo, C, Jain, N, Daver, N, Short, NJ, Jabbour, EJ, Kantarjian, HM. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American journal of hematology 97(7):856-864, 2022. PMID: 35357036.
113. Pollyea DA, CD D, Arellano ML, Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith BD, Shinagawa A, Lemoli RM, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Kantarjian HM. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clin Cancer Res 28(13):2753-2761, 2022. PMID: 35046058.
114. Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, Kantarjian HM, CD D, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Wei AH. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clin Cancer Res 28(13):2744-2752, 2022. PMID: 35063965.
115. Kim K, Konopleva M, CD D, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol 97(7):885-894, 2022. e-Pub 2022. PMID: 35413152.
116. Berkman AM, Andersen CR, Cuglievan B, McCall DC, Lupo PJ, Parsons SK, CD D, Short NJ, Jain N, Kadia TM, Livingston JA, Roth ME. Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiol Biomarkers Prev 31(6):OF1-OF9, 2022. e-Pub 2022. PMID: 35553621.
117. Post, SM, Ma, H, Malaney, P, Zhang, X, Aitken, MJ, Mak, PY, Ruvolo, VR, Yasuhiro, T, Kozaki, R, Chan, LE, Ostermann, LB, Konopleva, M, Carter, BZ, DiNardo, C, Andreeff, M, Khoury, J, Ruvolo, P. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica 107(6):1311-1322, 2022. PMID: 34732043.
118. Pemmaraju, N, Wilson, NR, Garcia-Manero, G, Sasaki, K, Khoury, J, Jain, N, Borthakur, G, Ravandi-Kashani, F, Daver, N, Kadia, TM, DiNardo, C, Jabbour, EJ, Pierce, S, Qazilbash, MH, Konopleva, M, Kantarjian, HM. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Advances 6(10):3027-3035, 2022. PMID: 35061885.
119. Senapati, J, Shoukier, M, Garcia-Manero, G, Wang, X, Patel, KP, Kadia, TM, Ravandi-Kashani, F, Pemmaraju, N, Ohanian, M, Daver, N, DiNardo, C, Alvarado, Y, Aldrich, J, Borthakur, G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. American journal of hematology 97(5):574-582, 2022. PMID: 35150150.
120. Yilmaz, M, Kantarjian, HM, Short, NJ, Reville, PK, Konopleva, M, Kadia, TM, DiNardo, C, Borthakur, G, Pemmaraju, N, Maiti, A, Jabbour, EJ, Jain, N, Issa, GC, Takahashi, K, Sasaki, K, Ohanian, M, Pierce, S, Tang, G, Loghavi, S, Patel, KP, Wang, S, Garcia-Manero, G, Andreeff, M, Ravandi-Kashani, F, Daver, N. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML. Blood cancer journal 12(5), 2022. PMID: 35501304.
121. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, CD D, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. PMID: 35483396.
122. Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, CD D, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther 7(1):110, 2022. e-Pub 2022. PMID: 35365596.
123. Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, Ivanov V, Schuh AC, CD D, Novak J, Pejsa V, Stevens D, Yeh SP, Kim I, Turgut M, Fracchiolla N, Yamamoto K, Ofran Y, Wei AH, Bui CN, Benjamin K, Kamalakar R, Potluri J, Mendes W, Devine J, Fiedler W. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J 12(4):71, 2022. e-Pub 2022. PMID: 35443742.
124. Short NJ, Borthakur G, Pemmaraju N, CD D, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma:1-10. e-Pub 2022. PMID: 35442137.
125. Gibson, A, Ragoonanan, D, Tewari, P, Petropoulos, D, Rodriguez, NI, DiNardo, C, Mahadeo, KM, Khazal, SJ. Non-myeloablative umbilical cord blood transplantation for atypical dyskeratosis congenita. Pediatric Transplantation 26(2), 2022. PMID: 34626046.
126. Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, CD D, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy: Revisiting the ELN Adverse Risk Classification. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
127. Pollyea DA, Barrett J, CD D, Michaelis LC, Roboz GJ, Le RQ, Norsworthy KJ, de Claro RA, Theoret MR, Pazdur R. Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia. Clin Cancer Res 28(5):816-820, 2022. PMID: 34753779.
128. Ramos Perez JM, Patel KP, Loghavi, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, CD D, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):1-4, 2022. e-Pub 2021. PMID: 34668451.
129. Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, CD D, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol 40(8):JCO2101546, 2022. e-Pub 2021. PMID: 34910556.
130. El Hussein S, CD D, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi S. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 57(3):370-376, 2022. e-Pub 2022. PMID: 34992253.
131. Mill CP, Fiskus W, CD D, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2021. PMID: 34601571.
132. Gibson, A, Trabal, AM, McCall, DC, Khazal, SJ, Toepfer, L, Bell, D, Roth, M, Mahadeo, KM, Nunez, CA, Short, NJ, DiNardo, C, Konopleva, M, Issa, GC, Ravandi-Kashani, F, Jain, N, Borthakur, G, Kantarjian, HM, Jabbour, EJ, Cuglievan, B. Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers 14(1), 2022. PMID: 35008312.
133. Venugopal, S, Takahashi, K, Daver, N, Maiti, A, Borthakur, G, Loghavi, S, Short, NJ, Ohanian, M, Masarova, L, Issa, GC, Wang, X, Bueso-Ramos, CE, Yilmaz, M, Kadia, TM, Andreeff, M, Ravandi-Kashani, F, Konopleva, M, Kantarjian, HM, DiNardo, C. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood cancer journal 12(1), 2022. PMID: 35078972.
134. Fiskus, WC, Boettcher, S, Daver, N, Mill, CP, Sasaki, K, Birdwell, C, Davis, JA, Takahashi, K, Kadia, TM, DiNardo, C, Jin, Q, Qi, Y, Su, X, McGeehan, G, Khoury, J, Ebert, BL, Bhalla, K. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood cancer journal 12(1), 2022. PMID: 35017466.
135. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol 97(1):68-78, 2022. e-Pub 2021. PMID: 34716921.
136. Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C, Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou N, Choi I, Miyazaki Y, Honda H, Okubo S, Kurokawa M, Zhou Y, Zha J, Potluri J, Matsumura I. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol 52(1):29-38, 2022. PMID: 34739075.
137. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad FG, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia TM, Garcia-Manero G, Garris R, O'Brien SM, Jabbour EJ. Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience. Blood Adv 5(23):5415-5419, 2021. e-Pub 2021. PMID: 34525185.
138. Kozyra EJ, Gohring G, Hickstein DD, Calvo KR, DiNardo CD, Dworzak M, de Haas V, Stary J, Hasle H, Shimamura A, Fleming MD, Inaba H, Lewis S, Hsu AP, Holland SM, Arnold DE, Mecucci C, Keel SB, Bertuch AA, Tawana K, Barzilai-Birenboim S, Hirabayashi S, Onozawa M, Lei S, Alaiz H, Andrikovics H, Betts D, Beverloo HB, Buechner J, Cermák M, Cervera J, Haus O, Jahnukainen K, Manola K, Nebral K, Pasquali F, Tchinda J, Turkiewicz D, Van Roy N, Zemanova Z, Pastor VB, Strahm B, Nöllke P, Niemeyer CM, Schlegelberger B, Yoshimi A, Wlodarski MW. Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations. Blood 138(23):2441-2445, 2021. e-Pub 2021. PMID: 34469508.
139. Thongon, N, Ma, F, Santoni, A, Marchesini, M, Fiorini, E, Rose, A, Ademà Llobet, V, Ganan Gomez, I, Groarke, EM, Gutierrez-Rodrigues, F, Chen, S, Lockyer, P, Schneider, S, Bueso-Ramos, CE, Montalban Bravo, G, Class, CA, Soltysiak, KA, Pellegrini, M, Sahin, E, Bertuch, AA, DiNardo, C, Garcia-Manero, G, Young, NS, Dwyer, KC, Colla, S. Hematopoiesis under telomere attrition at the single-cell resolution. Nature communications 12(1), 2021. PMID: 34824242.
140. Saxena, K, Jabbour, EJ, Issa, GC, Sasaki, K, Ravandi-Kashani, F, Maiti, A, Daver, N, Kadia, TM, DiNardo, C, Konopleva, M, Cortes, JE, Yilmaz, M, Chien, KS, Pierce, S, Kantarjian, HM, Short, NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. Journal of Hematology and Oncology 14(1), 2021. PMID: 34130720.
141. McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, Daver N, Kadia TM, DiNardo CD, Yi JS, Cuglievan B. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv 5(23):5215-5219, 2021. PMID: 34592761.
142. Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer 127(22):4213-4220, 2021. e-Pub 2021. PMID: 34343352.
143. Tanaka T, Morita K, Wang F, Loghavi S, Furudate K, Sasaki Y, Little LD, Gumbs CE, Matthews J, Daver NG, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal A, Takahashi K. Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood 138(18):1733-1739, 2021. e-Pub 2021. PMID: 34115096.
144. DiNardo, C, Stein, EM, Pigneux, A, Altman, JK, Collins, R, Erba, HP, Watts, JM, Uy, GL, Winkler, T, Wang, H, Choe, SE, Liu, H, Wu, B, Kapsalis, SM, Roboz, G, De Botton, S. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia 35(11):3278-3281, 2021. PMID: 33772143.
145. Tambaro, FP, Singh, H, Jones, E, Rytting, ME, Mahadeo, KM, Thompson, PA, Daver, N, DiNardo, C, Kadia, TM, Garcia-Manero, G, Chan, TA, Shah, RR, Wierda, WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35(11):3282-3286, 2021. PMID: 33833386.
146. Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Drazer MW, Yu K, Bödör C, Cantor A, Cazzola M, Degelman E, DiNardo CD, Duployez N, Favier R, Fröhling S, Fitzgibbon J, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Liu P, Godley LA, Schreiber AW, Hahn CN, Scott HS, Brown AL. The RUNX1 Database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica 106(11):3004-3007, 2021. e-Pub 2021. PMID: 34233450.
147. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
148. DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Döhner H. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 22(11):1597-1608, 2021. e-Pub 2021. PMID: 34672961.
149. Alwash Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, Daver N, Ravandi F, Kadia TM, Konopleva M, DiNardo CD, Issa GC, Loghavi S, Takahashi K, Jabbour E, Guerra V, Kornblau S, Kantarjian H, Short NJ. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol 96(11):1420-1428, 2021. e-Pub 2021. PMID: 34351647.
150. Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver NG, Pierce SR, Jabbour EJ, Kadia TM, DiNardo CD, Garcia-Manero G, Qazilbash MH, Konopleva MY, Kantarjian HM. Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood 138(15):1373-1377, 2021. e-Pub 2021. PMID: 34098573.
151. Venugopal S, Shoukier M, Konopleva M, DiNardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
152. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
153. Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127(20):3761-3771, 2021. e-Pub 2021. PMID: 34171128.
154. Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo CD. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J 11(10):163, 2021. e-Pub 2021. PMID: 34599139.
155. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
156. S Mehta R, Torres Cabala CA, DiNardo CD, Daver N, Dabaja B, Rezvani K, Champlin RE, Shpall E, Duvic M. Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. Am J Hematol 96(9):E350-E353, 2021. e-Pub 2021. PMID: 34096089.
157. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
158. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
159. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma:1-5. e-Pub 2021. PMID: 34474640.
160. Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo CD, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma:1-9. e-Pub 2021. PMID: 34380367.
161. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer 127(15):2641-2647, 2021. e-Pub 2021. PMID: 33823073.
162. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, DiNardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. PMID: 34329576.
163. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
164. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
165. Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo CD, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol 96(8):E275-E279, 2021. e-Pub 2021. PMID: 33891709.
166. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. PMID: 34424319.
167. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. PMID: 34110383.
168. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
169. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
170. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, CD D, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
171. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer 127(11):1894-1900, 2021. e-Pub 2021. PMID: 33449377.
172. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
173. Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. De novo acute myeloid leukemia: A population- based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer 127(12):2049-2061, 2021. e-Pub 2021. PMID: 33818756.
174. Fiskus, WC, Mill, CP, Nabet, B, Perera, D, Birdwell, C, Manshouri, T, Lara, BH, Kadia, TM, DiNardo, C, Takahashi, K, Daver, N, Bose, P, Masarova, L, Pemmaraju, N, Kornblau, SM, Borthakur, G, Montalban Bravo, G, Garcia-Manero, G, Sharma, S, Stubbs, M, Su, X, Green, M, Coarfa, C, Verstovsek, S, Khoury, J, Vakoc, CR, Bhalla, K. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood cancer journal 11(5), 2021. PMID: 34016956.
175. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and Venetoclax for IDH1/2-mutated Acute Myeloid Leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
176. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 12(1):2823, 2021. e-Pub 2021. PMID: 33972555.
177. Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun 12(1):2607, 2021. e-Pub 2021. PMID: 33972549.
178. Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
179. Stuani L, Sabatier M, Saland E, Cognet G, Poupin N, Bosc C, Castelli FA, Gales L, Turtoi E, Montersino C, Farge T, Boet E, Broin N, Larrue C, Baran N, Cissé MY, Conti M, Loric S, Kaoma T, Hucteau A, Zavoriti A, Sahal A, Mouchel PL, Gotanègre M, Cassan C, Fernando L, Wang F, Hosseini M, Chu-Van E, Le Cam L, Carroll M, Selak MA, Vey N, Castellano R, Fenaille F, Turtoi A, Cazals G, Bories P, Gibon Y, Nicolay B, Ronseaux S, Marszalek JR, Takahashi K, DiNardo CD, Konopleva M, Pancaldi V, Collette Y, Bellvert F, Jourdan F, Linares LK, Récher C, Portais JC, Sarry JE. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med 218(5), 2021. PMID: 33760042.
180. DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics 16(5):1-10, 2021. e-Pub 2020. PMID: 32856987.
181. Masarova, L, DiNardo, C, Bose, P, Pemmaraju, N, Daver, N, Kadia, TM, Chifotides, H, Zhou, L, Borthakur, G, Estrov, Z, Konopleva, M, Verstovsek, S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Advances 5(8):2156-2164, 2021. PMID: 33885751.
182. Lachowiez, C, Loghavi, S, Furudate, K, Montalban Bravo, G, Maiti, A, Kadia, TM, Daver, N, Borthakur, G, Pemmaraju, N, Sasaki, K, Alvarado, Y, Yilmaz, M, Short, NJ, Chien, KS, Ohanian, M, Pierce, S, Patel, KP, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, Takahashi, K, Konopleva, M, DiNardo, C. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Advances 5(8):2173-2183, 2021. PMID: 33885753.
183. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
184. Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood 137(13):1792-1803, 2021. e-Pub 2020. PMID: 33024987.
185. Loghavi, S, DiNardo, C, Furudate, K, Takahashi, K, Tanaka, T, Short, NJ, Kadia, TM, Konopleva, M, Kanagal Shamanna, R, Farnoud, N, Pierce, S, Khoury, J, Jorgensen, JL, Patel, KP, Daver, N, Yilmaz, M, Medeiros, LJ, Kantarjian, HM, Ravandi-Kashani, F, Wang, S. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. British Journal of Haematology 192(6):1054-1063, 2021. PMID: 33618432.
186. Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, CD D, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2020. PMID: 32561839.
187. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2020. PMID: 33681815.
188. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
189. Himes RW, Chiou EH, Queliza K, Shouval DS, Somech R, Agarwal S, Jajoo K, Ziegler DS, Kratz CP, Huang J, Lucas TL, Myers KC, Nelson AS, DiNardo CD, Alter BP, Giri N, Khincha PP, McReynolds LJ, Dufour C, Pierri F, Goldman FD, Sherif Y, Savage SA, Miloh T, Bertuch AA. Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. J Pediatr 230:55-61.e4, 2021. e-Pub 2020. PMID: 32971146.
190. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
191. Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS, Chyla B, Hong WJ, Jiang Q, Potluri J, DC. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol 96(2):208-217, 2021. e-Pub 2020. PMID: 33119898.
192. Sasaki, K, Jabbour, EJ, Ravandi-Kashani, F, Konopleva, M, Borthakur, G, Wierda, WG, Daver, N, Takahashi, K, Naqvi, K, DiNardo, C, Montalban Bravo, G, Kanagal Shamanna, R, Issa, GC, Jain, P, Skinner, J, Rios, MB, Pierce, S, Soltysiak, KA, Sato, J, Garcia-Manero, G, Cortes, JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase. American journal of hematology 96(2):241-250, 2021. PMID: 33180322.
193. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2020. PMID: 33119202.
194. Bannon, SA, Routbort, MJ, Montalban Bravo, G, Mehta, RS, Jelloul, FZ, Takahashi, K, Daver, N, Oran, B, Pemmaraju, N, Borthakur, G, Naqvi, K, Issa, GC, Sasaki, K, Alvarado, Y, Kadia, TM, Konopleva, M, Kanagal Shamanna, R, Khoury, J, Ravandi-Kashani, F, Champlin, RE, Kantarjian, HM, Bhalla, K, Garcia-Manero, G, Patel, KP, DiNardo, C. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Frontiers in Oncology 10, 2021. PMID: 33585199.
195. DiNardo, C, Konopleva, M. A venetoclax bench-to-bedside story. Nature Cancer 2(1):3-5, 2021. PMID: 35121895.
196. DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Döhner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 39(1):57-65, 2021. e-Pub 2020. PMID: 33119479.
197. Tanasijevic AM, Revette A, Klepin HD, Zeidan A, Townsley D, DiNardo CD, Sebert M, DeZern AE, Stone RM, Magnavita ES, Chen R, Sekeres MA, Abel GA. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leuk Lymphoma 61(12):1-5, 2020. e-Pub 2020. PMID: 32667230.
198. Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. PMID: 33351107.
199. Feurstein S, Zhang L, DiNardo CD. Accurate germline RUNX1 variant interpretation and its clinical significance. Blood Adv 4(24):6199-6203, 2020. PMID: 33351114.
200. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5996, 2020. e-Pub 2020. PMID: 33214561.
201. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. PMID: 33211826.
202. Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol 95(11):E313-E315, 2020. e-Pub 2020. PMID: 32804409.
203. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
204. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871-e882, 2020. e-Pub 2020. PMID: 32792304.
205. Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. PMID: 33112940.
206. DiNardo CD, Wang J, Pratz KW. Azacitidine and Venetoclax in AML. Reply. N Engl J Med 383(21):2088-2089, 2020. PMID: 33207106.
207. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
208. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
209. Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, CD D, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol 33(9):1678-1689, 2020. e-Pub 2020. PMID: 32238878.
210. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, CD D, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489-2492, 2020. e-Pub 2020. PMID: 32099037.
211. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, CD D, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma:1-8. e-Pub 2020. PMID: 32755333.
212. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Á I, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617-629, 2020. PMID: 32786187.
213. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, CD D, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. PMID: 32589978.
214. Lachowiez C, CD D, Konopleva M. Venetoclax in acute myeloid leukemia - current and future directions. Leuk Lymphoma 61(6):1-10, 2020. e-Pub 2020. PMID: 32031033.
215. Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short N, CD D, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
216. Wei AH, Montesinos P, Ivanov V, CD D, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. Blood 135(24):2137-2145, 2020. e-Pub 2020. PMID: 32219442.
217. Fan B, Dai D, DiNardo CD, Stein E, de Botton S, Attar EC, Liu H, Liu G, Lemieux I, Agresta SV, Yang H. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. Cancer Chemother Pharmacol 85(5):959-968, 2020. e-Pub 2020. PMID: 32296873.
218. Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo CD, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
219. Choe S, Wang H, CD D, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Watts JM, Pollyea DA, Fathi AT, Tallman MS, Kantarjian HM, Stone RM, Quek L, Konteatis Z, Dang L, Nicolay B, Nejad P, Liu G, Zhang V, Liu H, Goldwasser M, Liu W, Marks K, Bowden C, Biller SA, Attar EC, Wu B. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv 4(9):1894-1905, 2020. PMID: 32380538.
220. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, CD D, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
221. Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
222. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. PMID: 32251497.
223. Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel K, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. e-Pub 2020. PMID: 32356320.
224. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. e-Pub 2020. PMID: 32068780.
225. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol:1-7. e-Pub 2020. PMID: 32289808.
226. Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol 7(4):e309-e319, 2020. e-Pub 2020. PMID: 32145771.
227. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. PMID: 32330243.
228. Sasaki K, Kantarjian H, Wierda W, Ravandi F, Daver N, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Z, Konopleva M, Ohanian M, Garcia-Manero G, Kadia T, Alvarado Y, Yilmaz M, Pierce S, Garris R, Cortes J, O'Brien S, Ingram A, Jabbour E. Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Am J Hematol. e-Pub 2020. PMID: 32170867.
229. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791-803, 2020. PMID: 31932844.
230. Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo CD, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica 105(3):697-707, 2020. e-Pub 2019. PMID: 31123034.
231. Myers KC, Furutani E, Weller E, Siegele B, Galvin A, Arsenault V, Alter BP, Boulad F, Bueso-Ramos C, Burroughs L, Castillo P, Connelly J, Davies SM, DiNardo CD, Hanif I, Ho RH, Karras N, Manalang M, McReynolds LJ, Nakano TA, Nalepa G, Norkin M, Oberley MJ, Orgel E, Pastore YD, Rosenthal J, Walkovich K, Larson J, Malsch M, Elghetany MT, Fleming MD, Shimamura A. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol 7(3):e238-e246, 2020. e-Pub 2019. PMID: 31879230.
232. Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful Lenalidomide Treatment in High Risk Myelodysplastic Syndrome with Germline DDX41 Mutation. Am J Hematol 95(2):227-229, 2020. e-Pub 2019. PMID: 31400013.
233. Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood 135(7):463-471, 2020. e-Pub 2019. PMID: 31841594.
234. DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood 135(2):85-96, 2020. e-Pub 2019. PMID: 31765470.
235. Clifford M, Bannon S, Bednar EM, Czerwinski J, Davis J, Dunnington L, Shahrukh Hashmi S, CD D. Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies. Leuk Lymphoma 60(12):1-8, 2019. e-Pub 2019. PMID: 31274040.
236. Richard-Carpentier G, DiNardo CD. Single-agent and combination biologics in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2019(1):548-556, 2019. PMID: 31808888.
237. Tanaka T, Morita K, Wang F, Little L, Gumbs C, Matthews J, CD D, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Garcia-Manero G, Futreal PA, Takahashi K. Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood 134(Supplement_1):17, 2019. PMID: 31724013.
238. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, CD D, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. PMID: 31724006.
239. Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, CD D, Stein EM. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia 33(11):2575-2584, 2019. e-Pub 2019. PMID: 30967620.
240. Luo X, Feurstein S, Mohan S, Porter CC, Jackson SA, Keel S, Chicka M, Brown AL, Kesserwan C, Agarwal A, Luo M, Li Z, Ross JE, Baliakas P, Pineda-Alvarez D, CD D, Bertuch AA, Mehta N, Vulliamy T, Wang Y, Nichols KE, Malcovati L, Walsh MF, Rawlings LH, McWeeney SK, Soulier J, Raimbault A, Routbort MJ, Zhang L, Ryan G, Speck NA, Plon SE, Wu D, Godley LA. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Adv 3(20):2962-2979, 2019. PMID: 31648317.
241. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, CD D, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer 125(18):3219-3224, 2019. e-Pub 2019. PMID: 31150121.
242. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, CD D, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
243. Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DC. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma 60(9):1-7, 2019. e-Pub 2019. PMID: 30773968.
244. Alfayez M, Wang SA, Bannon SA, Kontoyiannis DP, Kornblau SM, Orange JS, Mace EM, DC. Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype. Leuk Lymphoma 60(8):1-9, 2019. e-Pub 2019. PMID: 30648453.
245. Agrusa JE, Bertuch AA, CD D, Plon SE, Eckstein OS. Severe therapy-related toxicities after treatment for Hodgkin lymphoma due to a pathogenic TERT variant and shortened telomeres. Pediatr Blood Cancer 66(8):e27779, 2019. e-Pub 2019. PMID: 31050187.
246. Quesada AE, Routbort MJ, CD D, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. DDX41 Mutations in Myeloid Neoplasms are Associated with Male Gender, TP53 Mutations and High-Risk Disease. Am J Hematol 94(7):757-766, 2019. e-Pub 2019. PMID: 30963592.
247. Mill CP, Fiskus W, CD D, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood 134(1):59-73, 2019. e-Pub 2019. PMID: 31023702.
248. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, CD D, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
249. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver N, CD D, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1-8, 2019. e-Pub 2019. PMID: 30632841.
250. Benton CB, Boddu PC, CD D, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer 125(11):1855-1866, 2019. e-Pub 2019. PMID: 30811597.
251. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, CD D, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer 125(10):1665-1673, 2019. e-Pub 2019. PMID: 30668890.
252. Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, CD D, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer 125(7):1091-1100, 2019. e-Pub 2018. PMID: 30521114.
253. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, CD D, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2018. PMID: 30409776.
254. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, CD D, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2018. PMID: 30635233.
255. Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, CD D, Medeiros LJ, Wang SA, Patel KP. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica 104(2):305-311, 2019. e-Pub 2018. PMID: 30171025.
256. Higgs C, Crow YJ, Adams DM, Chang E, Hayes D, Herbig U, Huang JN, Himes R, Jajoo K, Johnson FB, Reynolds SD, Yonekawa Y, Armanios M, Boulad F, CD D, Dufour C, Goldman FD, Khan S, Kratz C, Myers KC, Raghu G, Alter BP, Aubert G, Bhala S, Cowen EW, Dror Y, El-Youssef M, Friedman B, Giri N, Helms Guba L, Khincha PP, Lin TF, Longhurst H, McReynolds LJ, Nelson A, Olson T, Pariser A, Perona R, Sasa G, Schratz K, Simonetto DA, Townsley D, Walsh M, Stevens K, Agarwal S, Bertuch AA, Savage SA, Ailments (CCCTAA) CCCFT. Understanding the evolving phenotype of vascular complications in telomere biology disorders. Angiogenesis 22(1):95-102, 2019. e-Pub 2018. PMID: 30168024.
257. CD D, Perl AE. Advances in patient care through increasingly individualized therapy. Nat Rev Clin Oncol 16(2):73-74, 2019. PMID: 30602758.
258. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, CD D. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 5(1), 2019. e-Pub 2019. PMID: 30709875.
259. Stein EM, CD D, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 133(7):676-687, 2019. e-Pub 2018. PMID: 30510081.
260. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, CD D, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
261. CD D, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7-17, 2019. e-Pub 2018. PMID: 30361262.
262. Fiskus W, Cai T, CD D, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
263. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, CD D, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol 12(1):1, 2019. e-Pub 2019. PMID: 30606227.
264. Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, CD D, Luthra R, Medeiros LJ. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection. J Mol Diagn 21(1):89-98, 2019. PMID: 30577887.
265. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, CD D, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2018. PMID: 30328139.
266. Alfayez M, Ivan D, Pemmaraju N, Daver N, CD D. Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 30957058.
267. Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, CD D, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. PMID: 30501869.
268. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, CD D, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood 132(19):2100-2103, 2018. e-Pub 2018. PMID: 30242087.
269. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, CD D, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
270. Simon G, CD D, Takahashi K, Cascone T, Powers C, Stevens R, Allen J, Antonoff MB, Gomez D, Keane P, Suarez Saiz F, Nguyen Q, Roarty E, Pierce S, Zhang J, Hardeman Barnhill E, Lakhani K, Shaw K, Smith B, Swisher S, High R, Futreal PA, Heymach J, Chin L. Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. Oncologist. e-Pub 2018. PMID: 30446581.
271. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, CD D, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
272. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, CD D, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
273. CD D. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med 379(12):1186, 2018. PMID: 30231226.
274. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, CD D, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma 59(9):1-4, 2018. e-Pub 2018. PMID: 29338567.
275. Fathi AT, DiNardo CD, Kline I, Kenvin L, Gupta I, Attar EC, Stein EM, de Botton S, Investigators AS. Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. JAMA Oncol 4(8):1106-1110, 2018. e-Pub 2018. PMID: 29346478.
276. Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo CD, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97(7):1183-1191, 2018. e-Pub 2018. PMID: 29557496.
277. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9(1):2670, 2018. e-Pub 2018. PMID: 29991687.
278. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med 378(25):2386-2398, 2018. e-Pub 2018. PMID: 29860938.
279. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer 124(12):2534-2540, 2018. e-Pub 2018. PMID: 29645075.
280. Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, CD D, Gershenwald JE. Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol. e-Pub 2018. PMID: 29863571.
281. Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. e-Pub 2018. PMID: 30001986.
282. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36(18):JCO2017776757, 2018. e-Pub 2018. PMID: 29702001.
283. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. e-Pub 2018. PMID: 29769624.
284. Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol 14(10):979-993, 2018. e-Pub 2018. PMID: 29543066.
285. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28718728.
286. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93(3):401-407, 2018. e-Pub 2017. PMID: 29218851.
287. Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, DiNardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2017. PMID: 29134664.
288. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo CD, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
289. Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese LE, Ma W, Ma MCJ, DiNardo CD, Pierce SA, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Predictive gene signatures determine tumor sensitivity to MDM2 inhibition. Cancer Res. e-Pub 2018. PMID: 29490944.
290. Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, CD D, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol 7:26, 2018. e-Pub 2018. PMID: 30323983.
291. Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S, Konopleva M, Ravandi F, Cortes J, Kantarjian H, DiNardo CD. Influence of IDH on FLT3ITD status in newly diagnosed AML. Leukemia 31(11):2526-2529, 2017. e-Pub 2017. PMID: 28751773.
292. Kanagal-Shamanna R, Loghavi S, CD D, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102(10):1661-1670, 2017. e-Pub 2017. PMID: 28659335.
293. Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, CD D, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. e-Pub 2017. PMID: 28919634.
294. EM* S, * DC, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6):722-731, 2017. e-Pub 2017. PMID: 28588020.
295. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, CD D, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(7):1659, 2017. e-Pub 2017. PMID: 28338082.
296. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, CD D, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. e-Pub 2017. PMID: 28708931.
297. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, CD D, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica. e-Pub 2017. PMID: 28729302.
298. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, CD D, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. e-Pub 2017. PMID: 28616864.
299. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, CD D, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(18):2584-2587, 2017. e-Pub 2017. PMID: 28246192.
300. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, CD D, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
301. CD D, Luskin MR, Carroll M, Smith C, Harrison J, Pierce S, Kornblau S, Konopleva M, Kadia T, Kantarjian H, Wertheim GB, Master SR. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. Am J Hematol 92(2):E14-E15, 2017. PMID: 27804182.
302. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, CD D, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal column myelopathy after intrathecal chemotherapy for leukemia. Am J Hematol 92(2):155-160, 2017. PMID: 27874212.
303. Huang L, Wang SA, CD D, Li S, Hu S, Xu J, Zhou W, Goswami M, Medeiros LJ, Tang G. Tetraploidy/near-tetraploidy acute myeloid leukemia. Leuk Res 53:20-27, 2017. e-Pub 2016. PMID: 27951415.
304. Agarwal SK, CD D, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. Clin Ther 39(2):359-367, 2017. e-Pub 2017. PMID: 28161120.
305. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, CD D, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 123(3):426-435, 2017. e-Pub 2016. PMID: 27657543.
306. Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, CD D, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(2):318-324, 2017. e-Pub 2016. PMID: 27795561.
307. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, CD D, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294-302, 2017. e-Pub 2016. PMID: 27602508.
308. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, CD D, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18(1):100-111, 2017. e-Pub 2016. PMID: 27923552.
309. Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, CD D, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. e-Pub 2017. PMID: 28042144.
310. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, CD D, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2016. PMID: 27673440.
311. Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel PK, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, CD* D. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int. J. Mol. Sci, 2017. PMID: None.
312. DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea D. Safety and Efficacy of Venetoclax in Combination with Decitabine or Azacitidine in Patients Aged > 65 Years with Previously Untreated Acute Myeloid Leukemia Who Are Not Eligible for Standard Induction Therapy: A Non-randomized, Open-Label, Phase 1b Study. Lancet Oncology, 2017. PMID: None.
313. Birendra KC, CD D. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients with Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Clin Lymphoma Myeloma Leuk 16(8):460-5, 2016. e-Pub 2016. PMID: 27245312.
314. Zuo W, Wang SA, CD D, Yabe M, Li S, Medeiros LJ, Tang G. Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not MLL gene. J Clin Pathol. e-Pub 2016. PMID: 27496968.
315. Yin CC, Peng J, Li Y, Shamanna RK, Muzzafar T, DiNardo CD, Khoury JD, Li S, Medeiros LJ, Wang SA, Tang G. Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Mod Pathol 28(8):1014-22, 2016. PMID: 27469452.
316. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, CD D, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. e-Pub 2016. PMID: 27520294.
317. DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk 16(7):417-428.e2, 2016. e-Pub 2016. PMID: 27210295.
318. Goswami RS, Wang SA, DiNardo CD, Tang Z, Li Y, Zuo W, Hu S, Li S, Medeiros LJ, Tang G. Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. Mod Pathol 29(7):727-34, 2016. e-Pub 2016. PMID: 27056073.
319. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, DiNardo CD, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. e-Pub 2016. PMID: 27463065.
320. Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med 21(117):373-80, 2016. PMID: 27355333.
321. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo CD, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 7(12):14172-87, 2016. PMID: 26871476.
322. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo CD, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk 16(3):163-8.e1-2, 2016. e-Pub 2015. PMID: 26752456.
323. Ok CY, Leventaki V, Wang SA, DiNardo CD, Medeiros LJ, Konoplev S. Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy. Am J Clin Pathol 145(2):271-6, 2016. e-Pub 2016. PMID: 26800764.
324. Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, DiNardo CD, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30(2):268-73, 2016. e-Pub 2015. PMID: 26365212.
325. DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bueso-Ramos C, Jabbour E, Ravandi F, Cortes J, Kantarjian H. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol 91(2):227-32, 2016. PMID: 26799610.
326. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo CD, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncology 16(15):1547-55, 2015. PMID: None.
327. Badar T, Patel KP, Thompson PA, DiNardo CD, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research 39(12):1367-74, 2015. PMID: None.
328. Sanford D, CD D, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Jumping Translocations in Myeloid Malignancies Associated with Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk 15(9):556-62, 2015. e-Pub 2015. PMID: 26141213.
329. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Brandt M, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H. Characteristics, clinical outcome and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732-6, 2015. e-Pub 2015. PMID: 26016821.
330. Tang G, Goswami RS, Liang CS, Bueso-Ramos CE, Hu S, DiNardo CD, Medeiros LJ. Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant. Am J Clin Pathology 144(1):78-86, 2015. PMID: None.
331. Estécio MR, Maddipoti S, Bueso-Ramos C, DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS, Pierce SA, Bohannan Z, Borthakur G, Kantarjian H, Garcia-Manero G. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol 169(3):344-51, 2015. e-Pub 2015. PMID: 25612675.
332. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, DiNardo CD, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol 168(5):646-53, 2015. e-Pub 2014. PMID: 25312977.
333. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, William W, Bueso-Ramos C, Patel K, Cortes J, Ravandi R, Kantarjian H, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high -risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. The Lancet Haematology 2(1), 2015. PMID: None.
334. DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother 16(1):95-106, 2015. e-Pub 2014. PMID: 25480777.
335. Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo CD, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CE. Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J Natl Compr Canc Netw 13(1):19-22, 2015. PMID: 25583766.
336. DiNardo CD, Tang G, Pemmaraju N, Wang SA, Pike A, Garcia-Manero G, Cortes J, Bueso-Ramos C, Kantarjian HM. Acute Myeloid Leukemia With t(10;11): A Pathological Entity with Distinct Clinical Presentation. Clin Lymphoma Myeloma Leuk 15(1):47-51, 2015. e-Pub 2014. PMID: 25081372.
337. Tang G, DiNardo CD, Zhang L, Ravandi F, Khoury JD, Huh YO, Muzzafar T, Medeiros LJ, Wang SA, Bueso-Ramos CE. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation. Hum Pathol 46(1):65-73, 2015. e-Pub 2014. PMID: 25387813.
338. Quintás-Cardama A, Daver N, Kim H, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 2014. e-Pub 2014. PMID: 24875590.
339. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents. Leuk Lymphoma 55(8):1925-9, 2014. e-Pub 2014. PMID: 24138309.
340. Yang H, Bueso-Ramos C, DiNardo CD, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, Garcia-Manero G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280-8, 2014. e-Pub 2013. PMID: 24270737.
341. Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo CD, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the Revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol 89(1):509-16, 2014. e-Pub 2014. PMID: 24458781.
342. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 2014. e-Pub 2014. PMID: 24492324.
343. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, DiNardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia (aCML) BCR-ABL1-negative is clinicopathologically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms (MDS/MPN-U): a Bone Marrow Pathology Group study. Blood 123(17):2645-51, 2014. e-Pub 2014. PMID: 24627528.
344. DiNardo CD, Cortes JE. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. Expert Opin Investig Drugs 23(2):265-72, 2014. e-Pub 2013. PMID: 24313331.
345. DiNardo CD, Gharibyan V, Yang H, Wei Y, Pierce S, Kantarjian HM, Garcia-Manero G, Rytting M. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol 88(9):784-9, 2013. e-Pub 2013. PMID: 23757320.
346. DiNardo CD, O'Brien S, Gandhi VV, Ravandi F. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncol 9(8):1073-82, 2013. PMID: 23902239.
347. DiNardo CD, Ogdie A, Hexner EO, Frey NV, Loren AW, Luger SM. Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease. Leuk Lymphoma 54(6):1235-41, 2013. e-Pub 2013. PMID: 23216270.
348. DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, Litzow MR, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121(24):4917-24, 2013. e-Pub 2013. PMID: 23641016.
349. Attieh Y, Geng QR, DiNardo CD, Zheng H, Jia Y, Fang ZH, Gañán-Gómez I, Yang H, Wei Y, Kantarjian H, Garcia-Manero G. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood 121(19):4009-11, 2013. PMID: 23660862.
350. Dimicoli S, Wei Y, Bueso-Ramos C, Yang H, DiNardo CD, Jia Y, Zheng H, Fang Z, Nguyen M, Pierce S, Chen R, Wang H, Wu C, Garcia-Manero G. Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes. PLoS One 8(8):e71120, 2013. e-Pub 2013. PMID: 23976989.
351. CD D, Ky B, Vogl DT, Forfia P, Loren A, Luger S, Mato A, Tsai DE. Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Med Oncol 25(3):299-302, 2008. e-Pub 2008. PMID: 18181037.
352. Sheldon JP, Epstein Jayaratne T, Feldbaum MB, DiNardo CD, Petty EM. Applications and implications of advances in human genetics: perspectives from a group of Black Americans. Community Genet 10(2):82-92, 2007. PMID: 17380057.

Invited Articles

1. CD D, Perl AE. Advances in patient care through increasingly individualized therapy. Nat Rev Clin Oncology(2):73-74, 2019. PMID: 30602758.
2. Ragon K B, DiNardo CD. Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2017. PMID: 29064021.
3. DiNardo CD, Stone RM, Medeiros BC. Novel Therapeutics in Acute Myeloid Leukemia. Am Soc Clin Oncol Educ Book 37:495-503, 2017. PMID: 28561688.
4. Khan M, DiNardo CD. Great expectations in acute myeloid leukemia. Future Oncol 12(3):289-92, 2016. e-Pub 2016. PMID: 26768493.
5. Bannon SA, DiNardo CD. Hereditary Predispositions to Myelodysplastic Syndrome. Int J Mol Sci 17(6), 2016. e-Pub 2016. PMID: 27248996.
6. CD D, Luger SM. Minimal Residual Disease in AML: Beyond Morphology. Current Opinion in Hematology 19:82-88, 2012. PMID: None.
7. CD D, Tsai DE. Treatment advances in post-transplant lymphoproliferative disease. Curr Opin Hematol 17(4):368-374, 2010. PMID: 20473161.

Other Articles

1. Tomaszowski, KH, Roy, S, Guerrero, C, Shukla, P, Keshvani, C, Chen, Y, Ott, M, Wu, X, Zhang, J, DiNardo, C, Schindler, D, Schlacher, K Correction to. Nature communications 15(1), 2024. PMID: 38472265.
2. Cuglievan B, Kantarjian H, Rubnitz JE, Cooper TM, Zwaan CM, Pollard JA, DiNardo CD, Kadia TM, Guest E, Short NJ, McCall D, Daver N, Nunez C, Haddad FG, Garcia M, Bhalla KN, Maiti A, Catueno S, Fiskus W, Carter BZ, Gibson A, Roth M, Khazal S, Tewari P, Abbas HA, Bourgeois W, Andreeff M, Shukla NN, Truong DD, Connors J, Ludwig JA, Stutterheim J, Salzer E, Juul-Dam KL, Sasaki K, Mahadeo KM, Tasian SK, Borthakur G, Dickson S, Jain N, Jabbour E, Meshinchi S, Garcia-Manero G, Ravandi F, Stein EM, Kolb EA, Issa GC Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia 38(10):2073-2084, 2024. PMID: 39179671.
3. Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, Kadia T, Sasaki K, Short NJ, Yilmaz M, Ravandi F Current status and research directions in acute myeloid leukemia. Blood Cancer J 14(1):163, 2024. PMID: 39300079.
4. Marvin-Peek, J, Gilbert, JS, Pollyea, DA, DiNardo, C Frontline therapy of acute myeloid leukemia with lower intensity regimens. American journal of hematology 99(9):1790-1801, 2024. PMID: 39016070.
5. Chien KS, DiNardo CD, Garcia-Manero G Clonal hematopoiesis: malignant implications, extrahematologic manifestations, and management. Clin Adv Hematol Oncol 22(7):320-327, 2024. PMID: 39110659.
6. Jen, WY, Kantarjian, HM, Kadia, TM, DiNardo, C, Issa, GC, Short, NJ, Yilmaz, M, Borthakur, G, Ravandi-Kashani, F, Daver, N Combination therapy with novel agents for acute myeloid leukaemia. British Journal of Haematology 205(1):30-47, 2024. PMID: 38724457.
7. Godley LA, DiNardo CD, Bolton K Germline Predisposition in Hematologic Malignancies: Testing, Management, and Implications. Am Soc Clin Oncol Educ Book 44(3):e432218, 2024. PMID: 38768412.
8. DiNardo, C Toward an improved understanding of hypomethylating agent and venetoclax therapies. American journal of hematology 99(2):152-154, 2024. PMID: 38102772.
9. Chiu, CY, Matsuo, T, Wurster, ST, Gerstein, YS, Hammond, DE, Chien, KS, DiNardo, C, Kontoyiannis, DP Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML. Mycoses 66(12):1029-1034, 2023. PMID: 37550272.
10. DiNardo CD, Erba HP, Freeman SD, Wei AH Acute myeloid leukaemia. Lancet 401(10393):2073-2086, 2023. PMID: 37068505.
11. Lachowiez CA, DiNardo CD, Loghavi S Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance. Cancers (Basel) 15(5), 2023. PMID: 36900407.
12. Atluri H, Gerstein YS, CD D Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies. Curr Hematol Malig Rep 17(6):275-285, 2022. PMID: 36279069.
13. Desikan, SP, Daver, N, DiNardo, C, Kadia, TM, Konopleva, M, Ravandi-Kashani, F Resistance to targeted therapies. Blood cancer journal 12(6), 2022. PMID: 35680852.
14. Saxena, K, DiNardo, C, Daver, N, Konopleva, M SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML. Clinical Lymphoma, Myeloma and Leukemia 22(3):133-139, 2022. PMID: 34602371.
15. Lachowiez, C, DiNardo, C, Stein, EM Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia. Cancer Journal (United States) 28(1):21-28, 2022. PMID: 35072370.
16. Lachowiez CA, Atluri H, CD D Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia. Ther Adv Hematol 13:20406207221093964, 2022. PMID: 35510212.
17. Yilmaz, M, Alfayez, M, DiNardo, C, Borthakur, G, Kadia, TM, Konopleva, M, Loghavi, S, Kanagal Shamanna, R, Patel, KP, Jabbour, EJ, Garcia-Manero, G, Pemmaraju, N, Pierce, S, Issa, GC, Short, NJ, Montalban Bravo, G, Takahashi, K, Assi, R, Alotaibi, AS, Ohanian, M, Andreeff, M, Cortes, JE, Kantarjian, HM, Ravandi-Kashani, F, Daver, N Correction to. Journal of Hematology and Oncology 14(1), 2021. PMID: 33618754.
18. Kantarjian H, Short NJ, DiNardo CD, Stein EM, Daver N, Perl AE, Wang ES, Wei A, Tallman M Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol 8(12):e922-e933, 2021. PMID: 34687602.
19. Wei, A, Panayiotidis, P, Montesinos, P, Laribi, K, Ivanov, V, Kim, I, Novák, J, Stevens, DA, Fiedler, W, Pagoni, M, Bergeron, J, Ting, SB, Hou, JZ, Anagnostopoulos, A, McDonald, A, Murthy, V, Yamauchi, T, Wang, J, Chyla, B, Sun, Y, Jiang, Q, Mendes, W, Hayslip, JW, DiNardo, C Author Correction. Blood cancer journal 11(10), 2021. PMID: 34702803.
20. Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M Therapeutic implications of menin inhibition in acute leukemias. Leukemia 35(9):2482-2495, 2021. PMID: 34131281.
21. Salah, HT, DiNardo, C, Konopleva, M, Khoury, J Potential biomarkers for treatment response to the bcl-2 inhibitor venetoclax. Cancers 13(12), 2021. PMID: 34198580.
22. Issa GC, DiNardo CD Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J 11(6):107, 2021. PMID: 34083508.
23. Fathi AT, Stein EM, DiNardo CD, Levis MJ, Montesinos P, de Botton S Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. Am J Hematol 96(6):735-746, 2021. PMID: 33625753.
24. Isidori, A, Cerchione, C, Daver, N, DiNardo, C, Garcia-Manero, G, Konopleva, M, Jabbour, EJ, Ravandi-Kashani, F, Kadia, TM, Burguera, AF, Romano, A, Loscocco, F, Visani, G, Martinelli, G, Kantarjian, HM, Curti, A Immunotherapy in Acute Myeloid Leukemia. Frontiers in Oncology 11, 2021. PMID: 34041025.
25. Post, SM, Andreeff, M, DiNardo, C, Khoury, J, Ruvolo, P TAM kinases as regulators of cell death. Biochimica et Biophysica Acta - Molecular Cell Research 1868(6), 2021. PMID: 33647320.
26. Kantarjian, HM, Kadia, TM, DiNardo, C, Welch, MA, Ravandi-Kashani, F Acute myeloid leukemia. Cancer 127(8):1186-1207, 2021. PMID: 33734442.
27. Cerchione, C, Romano, A, Daver, N, DiNardo, C, Jabbour, EJ, Konopleva, M, Ravandi-Kashani, F, Kadia, TM, Martelli, MP, Isidori, A, Martinelli, G, Kantarjian, HM IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Frontiers in Oncology 11, 2021. PMID: 33898313.
28. Birdwell, C, Fiskus, WC, Kadia, TM, DiNardo, C, Mill, CP, Bhalla, K EVI1 dysregulation. Blood cancer journal 11(3), 2021. PMID: 33753715.
29. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, CD D, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):1-13, 2021. PMID: 32392559.
30. DiNardo CD, Korde LA, Yurgelun MB A Case-Based Approach to Understanding Complex Genetic Information in an Evolving Landscape. Am Soc Clin Oncol Educ Book 41(None):1-11, 2021. PMID: 34010053.
31. Kantarjian, HM, Kadia, TM, DiNardo, C, Daver, N, Borthakur, G, Jabbour, EJ, Garcia-Manero, G, Konopleva, M, Ravandi-Kashani, F Acute myeloid leukemia. Blood cancer journal 11(2), 2021. PMID: 33619261.
32. DiNardo, C Hypomethylating agents and venetoclax in acute myeloid leukemia. Clinical Advances in Hematology and Oncology 19(2):82-83, 2021. PMID: 33596188.
33. Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver N Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov 10(4):506-525, 2020. PMID: 32014868.
34. Stein EM, DiNardo CD, Pollyea DA, Schuh AC Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response. Clin Lymphoma Myeloma Leuk 20(2):e66-e75, 2020. PMID: 31862181.
35. Shah M, Rajha E, DiNardo CD, Muckey E, Wierda WG, Yeung SJ Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. Ann Emerg Med 75(2):264-286, 2020. PMID: 31561995.
36. CD D Which novel agents hold the greatest promise in AML?. Best Pract Res Clin Haematol 32(4):101106, 2019. PMID: 31779980.
37. Rafei H, CD D Hereditary myeloid malignancies. Best Pract Res Clin Haematol 32(2):163-176, 2019. PMID: 31203998.
38. Richard-Carpentier G, CD D Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol 10:2040620719882822, 2019. PMID: 31692757.
39. CD D, Stein EM SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML. Clin Lymphoma Myeloma Leuk. PMID: 30416011.
40. Abou Dalle I, DiNardo CD The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Ther Adv Hematol 9(7):163-173, 2018. PMID: 30013764.
41. DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer 124(13):2704-2713, 2018. PMID: 29682723.
42. Buege MJ, DiPippo AJ, CD D Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations. Cancers (Basel) 10(6), 2018. PMID: 29882807.
43. Medeiros BC, Fathi AT, CD D, Pollyea DA, Chan SM, Swords R Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia 31(2):272-281, 2017. PMID: 27721426.
44. DiNardo CD Isolated Myeloid Sarcoma of the Genitourinary System. Clin Adv Hematol Oncol 11(6):393-4, 2013. PMID: 24472812.
45. CD D, Luger SM Beyond morphology: minimal residual disease detection in acute myeloid leukemia. Curr Opin Hematol 19(2):82-8, 2012. PMID: 22314322.

Editorials

1. CD D, Garcia-Manero G, Kantarjian HM. Time to blur the blast boundaries. Cancer 128(8):1568-1570, 2022. PMID: 35133004.
2. DiNardo CD, Pollyea DA. Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. J Clin Oncol 40(8):811-813, 2022. PMID: 35007124.
3. DiNardo CD, Ravandi F. Time to Revise the Revised-International Prognostic Scoring System?. Leuk Lymphoma 56(12):1-7, 2015. PMID: 26037522.
4. DiNardo CD. Getting a handle on hereditary CEBPA mutations. Blood 126(10):1156-8, 2015. PMID: 26337351.

Abstracts

1. CD D, Schuh A, Stein E, Montesinos P, Wei A, de Botton S, Zeidan A, Fathi A, Kantarjian H, Martin-Regueira P, Lersch F, Maniar H, Gong J, Vyas P, Döhner H. Updated pharmacodynamic and survival outcomes from the AG221-AML-005 trial of Enasidenib (ENA) plus Azacitidine (AZA) in patients with mutant IDH2 newly diagnosed Acute Myeloid Leukemia (ND-AML). ESH 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
2. Venugopal S, Maiti A, CD D, Qiao W, Ning J, Loghavi S, Daver N, Kadia T, Rausch C, Alvarado Y, Ohanian M, Sasaki K, Short J N, Takahashi K, Yilmaz M, Ravandi F, Kantarjian H, Konopleva M. Prognostic impact of conventional cytogenetics in Acute Myeloid Leukemia (AML) treated with Decitabine and Venetoclax (DEC10-VEN). ESH 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
3. Yilmaz M, Kantarjian H, Muftuoglu M, CD D, Kadia T, Konopleva M, Borthakur G, Pemmaraju N, Short N, Alvarado Y, Maiti A, Montalban-Bravo G, Jurisprudencia J, Pike A, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib with Decitabine and Venetoclax (TRIPLET) is highly active in patients with FLT3-ITD mutated Acute Myeloid Leukemia . EHA 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
4. Siddiqui M, Maiti A, Daver N, Kadia T, Rausch C, Alvarado Y, Ohanian M, Short N, Takahashi K, Yilmaz M, Ravandi F, Kantarjian H, CD D, Konopleva M. Prognostic value of CRH in Acute Myeloid Leukemia treated with Venetoclax and Decitabine. ESH 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
5. Venugopal S, Takahashi K, Daver N, Borthakur G, Loghavi S, Short J N, Ohanian M, Masarova L, Issa C G, Bueso-Ramos C, Yilmaz M, Kadia T, Andreef M, Ravandi F, Konopleva M, Kantarjian H, CD D. Efficacy and safety of Enasidenib and Azacitidine combination in patients with IDH2 mutated Acute Myeloid Leukemia and not eligible for intensive chemotherapy. ESH 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
6. Lachowiez C, Borthakur G, Loghavi S, Zeng Z, Kadia T, Masarova L, Takahashi K, Tippett G, Smith S, Garcia J, Bose P, Jabbour E, Ravandi F, Daver D, Garcia-Manero G, Stoilova B, Vyas P, Kantarjian H, Konopleva M, CD D. A Phase IB/II Study of Ivosidenib with Venetoclax +/- Azacitidine in IDH1-Mutated Myeloid Malignancies. EHA 2021 Virtual Congress. HemaSphere, 2021. PMID: None.
7. Wei H A, Panayiotidis P, Montesinos P, Ivanov V, Novak J, Laribi K, Kim I, Stevens D, Fiedler M W, Bergeron J, Hou Z J, Murthy V, McDonald A, Yamauchi T, Ishizawa K, Wang J, Duan Y, Ghanim M T, Mendes W, DiNardo. Cytopenia Management in the Phase 3 Viale -C Study of Venetoclax plus low dose Cytarabine for patients with Newly diagnosed Acute Myeloid Leukemia ineligible for intensive chemotherapy. ESH 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
8. Pratz W K, Jonas A B, Pullarkat V, Recher C, Schuh C A, Thirman J M, Garcia S J, CD D, Vorobyev V, Fracchiolla N, Yeh P S, Jang H J, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, B Chyla B, Potluri J, Döhner H. Measurable Residual Disease Response in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. EHA 2021 Virtual Congress. HemaSphere, 2021. PMID: None.
9. Venugopal S, CD D, Takahashi K, Konopleva M, Loghavi S, Borthakur G, DeZern A, Masarova L, Daver N, Short J N, Alvarado Y, Ravandi F, Montalban-Bravo G, Sasaki K, Delumpa R, Sekeres A M, Patel B, Roboz J G, Kantarjian H, Garcia-Manero G. Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). EHA 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
10. Chua C C, Hammond D, Kent A, Tiong I S, Ong M D, Konopleva M, Pollyea A D, CD D, Wei H A. Treatment Free Remission (TFR) After Ceasing VENETOCLAX-BASED Therapy in Patients with Acute Myeloid Leukemia . EHA 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
11. Yilmaz M, Ravandi F, Loghavi S, Wang S, Borthakur G, CD D, Kadia T, Kanagal-Shammanna R, Pemmaraju N, Oran B, Popat U, Pierce S, Jabbour E, Short N, Issa G, Ohanian M, Garcia-Manero G, Andreeff M, Patel K, Konopleva M, Kantarjian H, Daver N. Triple combination of HMA, Venetoclax, and FLT3 Inhibitor produces higher FLT3 PCR clearance, flow MRD negativity , and improved median OS compared with doublets of HMA with FLT3 Inhibitor. ESH 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
12. DiNardo CD, Montesinos P, Schuh C A, Papayannidis C, Vyas P, Phil D, Wei H A, Zeidan M A, MD7, Bluemmert I, Yu X, Hasan M, Martin-Regueira P, de Botton S. Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 Identify Trial. Poster presentation, 63rd Annual ASH Meeting, 2021. ASH Abstract, 2021. PMID: None.
13. Yilmaz M, Ravandi F, Borthakur G, Kadia T, DiNardo, Kanagal-Shamanna R, Loghavi S, Oran B, Popat U, Pierce S, Jabbour E, Short N, Issa G, Pemmaraju N, Konopleva M, Patel K, Kantarjian H, Daver N. FLT3 INHIBITOR based induction and allogeneic stem cell transplant in CR1 improve outcomes in patients with newly diagnosed AML very low FLT3 allelic burden. ESH 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
14. CD D, Hartmut Dohner H, Zeidan M A, Schuh A, Vyas P, Phil D, Stein M E, Wei A H, de Botton S, Chen C, Lord-Bessen J, Martin-Regueira P, Lersch F, Gong J, Guo S, Shi L, Montesinos P. Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (mIDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC).Poster presentation, 63rd Annual ASH Meeting, 2021. ASH Abstract, 2021. PMID: None.
15. CD D, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei A, Ommen H, Semochkin S, Kim J H, Larson R, Koprivnikar J, Frankfurt O, Thol F, Chromik J, Byrne J, Pigneux A, Thomas X, Salamero O, Vidriales M B, Doronin V, Döhner H, Fathi A, Laille E, Yu X, Hasan M, Martin-Regueira P, de Botton S. A Phase 3 Study of Enasidenib ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant -IDH2 (MIDH2) relapsed/ refractory Acute Myeloid Leukemia (R/R AML). ESH 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
16. Saxena K, Jabbour E, Issa G, Sasaki K, Maiti A, Ravandi F, Daver N, Kadia T, CD D, Konopleva M, Chien K, Pierce S, Kantarjian H, Short. Frontline treatment approaches for CML in Myeloid Blast Phase: A single – center experience over 2 decades. HemaSphere, 2021. PMID: None.
17. Pullarkat V, Pratz W K, Döhner H, Recher C, Thirman J M, DiNardo, Fenaux P, Schuh C A, Wei H A, Pigneux A, Jang H J, Juliusson G, Miyazaki Y, Selleslag D, Arellano L M, Naqvi K, Yu J, Ridgeway A J, Potluri J, Konopleva M. Venetoclax and Azacitidine combination in chemotherapy ineligible patients with therapy - related Myeloid neoplasms, Antecedent Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative neoplasms. ESH 2021 Virtual Meeting. HemaSphere, 2021. PMID: None.
18. CD D, Lachowiez C, Borthakur G, Loghav S, Zeng Z, Kadia T, Masarova L, Takahashi K, Naqvi K, Bose P, Jabbour, Ravandi E, Daver N, Guillermo GM, Stoilova B, Vyas P, Kantarjian H, Konopleva M. Phase IB/II Study of The IDH1 – Mutant Inhibitor Ivosidenib with the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1 – Mutated Hematologic Malignancies. EHA Abstract, 2020. PMID: None.
19. DiNardo CD, De Botton S, Stein EM, Roboz GJ, Mims AS, Pollyea DA, Swords R, Altman JK, Collins RH, Mannis GN, Uy GL, Donnellan W, Pigneux A, Fathi AT, Stein AS, Erba HP, Prince GT, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Yen K, Kapsalis SM, Liu H, Goldwasser M, Agresta S, Attar EC, Tallman MD, Stone RM, Kantarjian H. Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. 59th Annual ASH Meeting, 2017. ASH Abstract, 2017. PMID: None.
20. DiNardo CD, Stein AS, Fathi AT, Montesinos P, Odenike O, Kantarjian H, Stone RM, Koralek DO, Oostendorp JV, Gong J, Gupta I, Vyas, DPhil P. Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). 59th Annual ASH Meeting, 2017. ASH Abstract, 2017. PMID: None.
21. DiNardo CD, Pollyea DA, Jonas BA, Konopleva M, Pullarkat V, Wei A, Kantarjian H, Pigneux A, Recher C, Seymour JF, Dunbar M, Xu T, Mabry M, Potluri J, Pratz K, LA. Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia. Poster presentation, 59th Annual ASH Meeting, 2017. ASH Abstract, 2017. PMID: None.
22. Stein M E, CD D, Altman K J, Collins R, DeAngelo J D, Kantarjian M H, Sekeres A M, Fathi T A, Flinn W I, Frankel E A, Levine L R, Medeiros C B, Patel R M, Pollyea D, Roboz JG, Stone MR, Swords T R, Tallman S M, Yen K, Attar CE, Xu Q, Tosolini A, Mei M J, Thakurta A, Knight D R, De Botton S. Safety and Efficacy of AG221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. 57th Annual ASH Meeting, 2015. ASH Abstract, 2015. PMID: None.
23. DiNardo CD, Pollyea D, Pratz K, Thirman MJ, Letai A, Frattini M, Jonas B, Leverson J, Zhu M, Dunbar M, Falotico N, Kirby R, Agarwal S, Mabry M, Potluri J, Humerickhouse RA, Kantarjian HM, Konopleva M. A Phase 1b Study of Venetoclax (ABT-199) in Combination with Decitabine or Azacitidine in Treatment-Naïve Patients with Acute Myelogenous Leukemia Who are > 65 years and Not Eligible for Standard Induction Therapy. ASH 2015 Oral Abstract. Blood 126(327), 2015. PMID: None.
24. DiNardo C, Pollyea D, Pratz K. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are >65 years and not eligible for standard induction therapy. Presented at: 2015 ASH Annual Meeting; December 5-8, 2015; Orlando, Florida. Abstract 327. ASH Abstract, 2015. PMID: None.
25. DiNardo CD, De Botton S, Pollyea A D, Stein M E, Fathi T A, Roboz J G, Collins R, Swords T R, Flinn W I, Altman K J, Tallman S M, Kantarjian M H, Derti A, Goldwasser M, Prahl M, Agresta S, Stone M R. Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study. 57th Annual ASH Meeting, 2015 - Poster presentation. ASH Abstract, 2015. PMID: None.
26. Jabbour E, Sasaki K, Daver N, Pemmaraju N, Jain N, Kadia T, DiNardo CD, Borthakur G, Konopleva M, Faderl S, O'Brien S, Cortes JE, Kantarjian H, Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
27. Navada SC, Garcia-Manero G, Wilhelm F, Hearn K, Odchimar-Reissig R, Demakos EP, Alvarado Y, Daver N, DiNardo C, Konopleva M, Borthakur G, Azarnia N, Silverman LR. A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
28. Daver NG, Kantarjian H, O'Brien S, Jabbour E, Pierce S, Lim M, Borthakur G, Pemmaraju N, Konopleva M, CD &D, Ravandi F, Garcia-Manero G, Cortes JE. Frequency and Impact of Molecular Response’s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
29. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Wei Y, Wierda W, Bueso-Ramos C, Patel K, Cortes JE, Ravandi F, Kantarjian H, Garcia-Manero G. Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher- Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). 56th Annual ASH Meeting 2014. ASH Abstract, 2014. PMID: None.
30. Pinnamaneni P, Jorgensen J, Kantarjian H, Jabbour E, Pierce S, Brandt M, Wang SA, Konoplev SJ, Konopleva M, Kornblau SM, Kadia T, DiNardo CD, Pemmaraju N, Andreeff M, Estrov Z, Garcia-Manero G, Cortes JE, Ravandi F. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia. 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
31. Kadia T, Borthakur G, Ferrajoli A, Daver N, Jabbour E, Pemmaraju N, Verstovsek S, Burger JA, Wierda W, Konopleva M, DiNardo CD, Jain N, Brandt M, Tuttle C, Wang X, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian H. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
32. Konopleva M, Pollyea D, Potluri J, Chyla B, Busman T, McKeegan E, Salem A, Zhu M, Ricker J, Blum W, DiNardo CD, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone, Kantarjian H, Letai A. A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML). 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
33. Pemmaraju N, Kantarjian H, O'Brien S, Borthakur G, Ravandi F, Verstovsek S, Daver NG, Garcia-Manero G, DiNardo CD, Skinner J, Konopleva M, Pierce S, Jabbour E, Cortes JE. Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
34. Konopleva M, Pollyea DA, Potluri J, Chyla BJ, Busman T, Salem A, Zhu M, Ricker JL, Blum W, DiNardo CD, Dunbar M, Kirby R, Falotico N, Leverson JD, Humerickhouse RA, Mabry M, Stone RM, Kantarjian HM, Letai AC. A Phase 2 Study of ABT-199 in Patients with Acute Myelogenous Leukemia. ASH 2014 oral abstract. Blood, 2014. PMID: None.
35. Jabbour E, Sasaki K, Daver N, Pemmaraju N, DiNardo CD, Kadia T, Miller D, Sukholutsky V, Huang X, Borthakur G, Estrov Z, Kantarjian H, Garcia-Manero G. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
36. Garcia-Manero G, Huang X, Cabrero M, DiNardo CD, Pemmaraju N, Daver NG, Borthakur G, Wierda W, Kadia T, Alvarado Y, Cortes JE, Jain N, Ravandi F, Jabbour E, Brandt M, Sneed T, Sukholutsky V, Pierce S, Bohannan Z, Kantarjian H. A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
37. DiNardo CD, Aung F, Martinez F, Daver N, Kadia T, Jain N, Jabbour E, Pemmaraju N, Reddy V, Garcia-Manero G, Cortes JE, Ravandi F, Kantarjian H, Lichtiger B, Freireich E. Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy. 56th Annual ASH Meeting 2014. ASH Abstract, 2014. PMID: None.
38. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Wei Y, Wierda W, Bueso-Ramos C, Patel K, Cortes JE, Ravandi F, Kantarjian H, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
39. Cabrero M, Jabbour E, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia T, Pemmaraju N, Kantarjian H, Garcia-Manero G. Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
40. Jabbour E, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Gail RJ, Daver N, Pemmaraju N, Kadia T, DiNardo CD, Wang X, Nogueras-Gonzalez G, Borthakur G, Estrov Z, Kantarjian H, Garcia-Manero G. Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
41. Cabrero M, Garcia-Manero G, Sasaki K, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia TM, Pemmaraju N, Oran B, Champlin RE, Kantarjian H, Jabbour E. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
42. Daver N, Kantarjian H, Garcia-Manero G, Pemmaraju N, Kadia T, DiNardo CD, Jain N, Borthakur G, Jabbour E, Konopleva M, Cortes JE, Craig A, Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
43. Sasaki K, Jabbour E, Pemmaraju N, Daver NG, Kadia TM, DiNardo CD, Pierce S, Borthakur G, Kantarjian H, Garcia-Manero G. Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
44. Estecio M, Maddipoti S, DiNardo CD, Yang H, Stevenson W, Bueso-Ramos C, Pierce S, Wei Y, Garcia-Manero G. Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype. 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
45. Patel K, Routbort M, Noguera-Gonzalez G, Kantarjian H, Jabbour E, Borthakur G, DiNardo CD, Estrov Z, Daver NG, Wierda W, Jain N, O'Brien S, Konopleva M, Cortes JE, Pemmaraju N, Alvarado Y, Bueso-Ramos C, Luthra R, Singh R, Pierce S, Jeffrey Medeiros L, Bohannan Z, Huang X, Garcia-Manero G. Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
46. Matre P, Shariati M, Velez J, Qi Y, Konoplev S, Su X, DiNardo CD, Daver N, Majeti R, Andreeff M, Chan SM, Konopleva M. Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia. 56th Annual ASH Meeting, 2014. ASH Abstract, 2014. PMID: None.
47. Elias J, Kantarjian H, Qiao W, Strati P, Khan N, Cortes JE, Hoehn D, Hu J, O'Brien S, Bryan J, Prescott H, DiNardo CD, Daver N, Kadia T, Garcia-Manero G. Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA). 2013 ASH Annual Meeting. Blood 122(21), 2013. PMID: None.
48. Nazha A, Garcia-Manero G, Kantarjian H, Ravandi F, Borthakur G, Kadia T, Jabbour E, Pemmaraju N, Daver N, DiNardo CD, Miller D, Faderl S. Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy . 2013 ASH Annual Meeting. Blood 122(21), 2013. PMID: None.
49. Thomas D, Faderl S, Bass J, Wierda W, Daver N, DiNardo CD, Pierce S, Brandt M, Kantarjian H, Garcia - Manero G. A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. 2013 ASH Annual Meeting. Blood 122(21), 2013. PMID: None.
50. Daver N, KadiaT, DiNardo CD, Ravandi F, Nazha A, Borthakur G, Pemmaraju N, Brandt M, O'Brien S, Garcia-Manero G, Pierce S, Jabbour E, Cortes JE, Kantarjian H. Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age . 2013 ASH Annual Meeting. Blood 122(21), 2013. PMID: None.
51. Nazha A, Kantarjian H, Jabbour E, DiNardo CD, Borthakur G, Daver N, Faderl F, Ning J, Qiao W, Ravandi F, Kadia T, Pierce S, Cortes JE, Garcia - Manero G. Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy. 2013 ASH Annual Meeting. Blood 122(21), 2013. PMID: None.
52. Hu C, Qutub A, Qiu Y, Yoo S, Zhang N, Pemmaraju N, DiNardo CD, Coombes K, Kornblau S. A Global Proteomic Pathway Map In Acute Myeloid Leukemia (AML) . 2013 ASH Annual Meeting. Blood 122(21), 2013. PMID: None.
53. Frey N, Hexner E, Porter D, Mangan J, Loren A, Hatem J, Bagg A, Perl A, Tsai D, CD D, Heitjian D, Luger S, Carroll M. A Phase I Clinical Trial using Eltrombopag in Patients with Acute Myelogenous Leukemia. ASH Abstract, 2012. PMID: None.
54. CD D, Ogdie A, Hexner EO, Frey NV, Loren AW, Luger SM. Characteristics and outcome of AML in patients with a prior history of autoimmune disease. ASCO Abstract, 2012. PMID: None.
55. DiNardo CD, Loren AW, Goldstein S, Schuster S, Perl AE, Tsai DE, Frey NV, Hexner EO, Reshef R, Stadtmauer E, Porter D, Luger SM. Outcomes of myeloablative hematopoietic stem cell transplantation for patients with acute myelogenous leukemia with relapsed or refractory disease. ASH Abstract, 2010. PMID: None.

Book Chapters

1. and O’Brien DC, S. Prognostic Markers and Management of CLL. In: Expert Clinical Perspective: Controversies and Uncertainties in Diagnosis & Management of Cancer. None. Wiley-Blackwell Publishers, 2013.

Letters to the Editor

1. Dimopoulos YP, Wang W, Wang SA, Loghavi S, DiNardo CD, Gerstein Y, Hu S, Tang Z, Ilagan CJL, Thakral B, El Hussein S, Xu J, Li S, Lin P, Patel KP, Ok CY, Medeiros LJ, Fang H. The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome. Am J Hematol None: None, 2024.
2. Mustafayev K, Yepez Guevara E, DiNardo CD, Jabbour E, Ghayas IC, Ratan R, Pemmaraju N, Torres HA. Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. Leuk Res 147: 107597, 2024.
3. Nasnas, PE, Ling, J, Gerstein, YS, Wang, S, Loghavi, S, Hammond, DE, Montalban Bravo, G, Senapati, J, Pemmaraju, N, Corredor, J, Pierce, S, Roth, M, Ravandi-Kashani, F, Cuglievan, B, Kadia, TM, DiNardo, C. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes. Clinical Lymphoma, Myeloma and Leukemia 24: 732-735, 2024.
4. Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Sasaki K, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma 65: 1511-1515, 2024.
5. Gruszczynska A, Maiti A, Miller CA, Ramakrishnan SM, Link DC, Uy GL, Petti AA, Hayes K, DiNardo CD, Ravandi F, Ley TJ, Spencer DH, Gao F, Konopleva MY, Welch JS. Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes. Haematologica 109: 2653-2659, 2024.
6. Abuasab, T, Borthakur, G, Kanagal Shamanna, R, Masarova, L, Patel, KP, Takahashi, K, Bose, P, Villarreal, J, Pierce, S, Kadia, TM, Garcia-Manero, G, Short, NJ, DiNardo, C, Daver, N, Ravandi-Kashani, F, Kantarjian, H, Verstovsek, S, Yilmaz, M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms. American journal of hematology 99: 1434-1436, 2024.
7. Montalban Bravo, G, Rodriguez-Sevilla, JJ, Swanson, DM, Kanagal Shamanna, R, Hammond, DE, Chien, KS, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
8. Bataller, A, DiNardo, C, Bazinet, A, Daver, N, Maiti, A, Borthakur, G, Short, NJ, Sasaki, K, Jabbour, EJ, Issa, GC, Pemmaraju, N, Yilmaz, M, Montalban Bravo, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. American journal of hematology 99: 792-796, 2024.
9. Bataller, A, Abuasab, T, McCall, DC, Wang, W, Cuglievan, B, Issa, GC, Jabbour, EJ, Short, NJ, DiNardo, C, Tang, G, Garcia-Manero, G, Kantarjian, HM, Sasaki, K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. Haematologica 109: 293-297, 2024.
10. Hammond, DE, Loghavi, S, Wang, SA, Konopleva, M, Kadia, TM, Daver, N, Ohanian, M, Issa, GC, Alvarado, Y, Short, NJ, Sasaki, K, Pemmaraju, N, Montalban Bravo, G, Lachowiez, C, Maiti, A, Garcia-Manero, G, Jabbour, EJ, Borthakur, G, Ravandi-Kashani, F, Takahashi, K, Pierce, SR, Kantarjian, HM, DiNardo, C. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood cancer journal 13, 2023.
11. DiNardo, C, De Botton, S, Pollyea, DA, Stone, RM, Altman, JK, Fathi, AT, Limsakun, T, Liang, M, Choe, SE, Hossain, M, Tron, AE, Meng, Q, Kapsalis, SM, Pandya, SS, Stein, EM. Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies. American journal of hematology 98: E233-E236, 2023.
12. Senapati, J, Abuasab, T, Haddad, FG, Ravandi-Kashani, F, Kadia, TM, DiNardo, C, Daver, N, Pemmaraju, N, Alvarado, Y, Brandt, M, Kantarjian, HM, Borthakur, G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. American journal of hematology 98: E53-E56, 2023.
13. Short, NJ, Macaron, W, Kadia, TM, DiNardo, C, Issa, GC, Daver, N, Wang, S, Jorgensen, JL, Nguyen, D, Bidikian, A, Patel, KP, Loghavi, S, Konopleva, M, Yilmaz, M, Jabbour, EJ, Maiti, A, Abbas, HA, Shpall, E, Popat, UR, Al-Atrash, G, Pierce, S, Kantarjian, HM, Ravandi-Kashani, F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. American journal of hematology 97: E408-E411, 2022.
14. Gangat, N, Konopleva, M, Patnaik, MM, Jabbour, EJ, DiNardo, C, Al-Kali, A, Foran, J, Granroth, GL, Olteanu, H, Kadia, TM, Tefferi, A, Pemmaraju, N. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. American journal of hematology 97: E62-E67, 2022.
15. Fiskus, WC, Manshouri, T, Birdwell, C, Mill, CP, Masarova, L, Bose, P, Kadia, TM, Daver, N, DiNardo, C, Borthakur, G, Khoury, J, Verstovsek, S, Bhalla, K. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood cancer journal 12, 2022.
16. Diao, S, Nichols, ED, DiNardo, C, Konopleva, M, Ning, J, Qiao, W, Maiti, A, DiPippo, AJ. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax. American journal of hematology 96: E65-E68, 2021.
17. Reville, PK, Kantarjian, HM, Ravandi-Kashani, F, Jabbour, EJ, DiNardo, C, Daver, N, Pemmaraju, N, Ohanian, M, Alvarado, Y, Xiao, L, Al-Atrash, G, Loghavi, S, Rausch, CR, Borthakur, G, Konopleva, M, Cortes, JE, Kadia, TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients. Blood cancer journal 11, 2021.
18. Maiti, A, DiNardo, C, Daver, N, Rausch, CR, Ravandi-Kashani, F, Kadia, TM, Pemmaraju, N, Borthakur, G, Bose, P, Issa, GC, Short, NJ, Yilmaz, M, Montalban Bravo, G, Ferrajoli, A, Jabbour, EJ, Jain, N, Ohanian, M, Takahashi, K, Thompson, PA, Loghavi, S, Montalbano, K, Pierce, S, Wierda, WG, Kantarjian, HM, Konopleva, M. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood cancer journal 11, 2021.
19. Montalban Bravo, G, Kanagal Shamanna, R, Guerra, VA, Ramos Perez, JM, Hammond, DE, Shilpa, P, Naqvi, K, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Konopleva, M, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Estrov, Z, Khoury, J, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Patel, KP, Kantarjian, HM, Garcia-Manero, G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American journal of hematology 96: E50-E53, 2021.
20. CD D, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia 30: 980-4, 2016.